Vorinostat (SAHA)

Name: Vorinostat (SAHA)
Brand: Selleck Chemicals
SKU: S1047
Rating: 5 (309 reviews)

For research use only.

Catalog No.S1047 Synonyms: MK0683

309 publications

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Selleck's Vorinostat (SAHA) has been cited by 309 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2020, 13;37(4):599-617 e7

PubMed: 32243837 ( click the link to review the publication )

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Cell Metab, 2018, 5;27(6):1294-1308.e7

PubMed: 29754954 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 28;158(5):989-999.

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 10;471(7337):235-9.

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa088

PubMed: 32107550 ( click the link to review the publication )

EMBO Rep, 2020, 21:e50162

PubMed: 32314873 ( click the link to review the publication )

J Immunother Cancer, 2020, 8(1)

PubMed: 31940587 ( click the link to review the publication )

Theranostics, 2020, 1;10(3):1433-1453

PubMed: 31938073 ( click the link to review the publication )

Cancer, 2020, 1;126(9):2024-2033

PubMed: 31999837 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Clin Epigenetics, 2020, 12(1):13

PubMed: 31941522 ( click the link to review the publication )

Br J Cancer, 2020, 27

PubMed: 32336756 ( click the link to review the publication )
Front Cell Dev Biol, 2020, 17;8:158

PubMed: 32258036 ( click the link to review the publication )

J Neuroinflammation, 2020, 22;17(1):125

PubMed: 32321538 ( click the link to review the publication )

ACS Infect Dis, 2020, 29

PubMed: 32347704 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

J Virol, 2020, 4;94(10) pii: e01923-19

PubMed: 32161174 ( click the link to review the publication )

Biochem Pharmacol, 2020, 3;178:114067

PubMed: 32504550 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

PLoS One, 2020, 15;15(5):e0232985

PubMed: 32413049 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):460-468

PubMed: 31897159 ( click the link to review the publication )

Colloids Surf B Biointerfaces, 2020, 188:110753

PubMed: 31884084 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Genes Dev, 2020, 34(5-6):428-445

PubMed: 32001510 ( click the link to review the publication )

Life Sci, 2020, 248:117469

PubMed: 32109485 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

Pharm Biol, 2020, 58(1):231-238

PubMed: 32202448 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4192

PubMed: 31519896 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )
Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Cancer Discov, 2019, 9(4):526-545

PubMed: 30709805 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Oncol, 2019, 10.1002/1878-0261.12607

PubMed: 31782885 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656155

PubMed: 31423895 ( click the link to review the publication )

Epigenetics, 2019, 14(8):791-803

PubMed: 31088315 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Hum Mol Genet, 2019, 10.1093/hmg/ddz254

PubMed: 31691806 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

Bone, 2019, 125:112-121

PubMed: 31100533 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(13)

PubMed: 31269745 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )
Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Gene Ther, 2019, 26(3-4):75-85

PubMed: 30538307 ( click the link to review the publication )

Cancer Med, 2019, 8(14):6383-6392

PubMed: 31456359 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0218382

PubMed: 31206526 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Nucl Med Biol, 2019, 74-75:1-11

PubMed: 31421440 ( click the link to review the publication )

Alcohol, 2019, 78:79-87

PubMed: 30851364 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Host Microbe, 2018, 24(5):689-702

PubMed: 30344003 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

Haematologica, 2018, 103(4):679-687

PubMed: 29305415 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Acta Biomater, 2018, 71:261-270

PubMed: 29526828 ( click the link to review the publication )
Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(5):2600-2611

PubMed: 29461008 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Microbiol, 2018, 9:2022

PubMed: 30283406 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):466

PubMed: 29695239 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

AAPS PharmSciTech, 2018, 19(2):634-647

PubMed: 28948528 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Alcohol Clin Exp Res, 2018, 42(11):2160-2171

PubMed: 30103280 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(1):47-54

PubMed: 27870832 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Oncogene, 2017, 36(34):4859-4874

PubMed: 28414307 ( click the link to review the publication )
Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(20):3608-3622

PubMed: 28749535 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

Eur J Med Chem, 2017, 141:596-602

PubMed: 29102179 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1485-1492

PubMed: 28498513 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(5)

PubMed: 28481295 ( click the link to review the publication )

J Biol Chem, 2017, 292(12):5043-5054

PubMed: 28167529 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45687-45697

PubMed: 28537899 ( click the link to review the publication )

Oncotarget, 2017, 9(1):512-523

PubMed: 29416632 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51429-51446

PubMed: 28881658 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 8(45):78480-78495

PubMed: 29108243 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )
Cell Host Microbe, 2017, 21(5):569-579

PubMed: 28494238 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Cancer Res, 2016, 76(8):2376-83

PubMed: 26941288 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

mBio, 2016, 7(6)

PubMed: 27803184 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Sci Rep, 2016, 6:38219

PubMed: 27910887 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2016, 311(5):H1139-H1149

PubMed: 27638876 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Med Oncol, 2016, 33(2):11

PubMed: 26732474 ( click the link to review the publication )
Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(8):e0160826

PubMed: 27536989 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Asian Pac J Trop Med, 2016, 9(6):572-6

PubMed: 27262069 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 8(62):104733-104744

PubMed: 29285209 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Oncotarget, 2016, 7(6):6727-47

PubMed: 26734995 ( click the link to review the publication )

Nat Commun, 2015, 6:7888

PubMed: 26223951 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

EBioMedicine, 2015, 3:108-121

PubMed: 26870822 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1657

PubMed: 25695609 ( click the link to review the publication )
Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Vis, 2015, 21:502-14

PubMed: 25999677 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Circ Heart Fail, 2015, 8(6):1094-104

PubMed: 26371176 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Acta Neuropathol, 2014, 128(2):291-303

PubMed: 24839957 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )
Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Oncogene, 2014, 33(25):3307-15

PubMed: 23995789 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2014, 14(1):112

PubMed: 25546354 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Virology, 2014, 462-463:328-39

PubMed: 25014309 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )
Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 14;121(11):2038-50

PubMed: 23327920 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

PLoS Comput Biol, 2013, 9(2):e1002887

PubMed: 23408876 ( click the link to review the publication )
Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 8;120(19):3958-67

PubMed: 22983447 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )
Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	NWfH[IxtU2mwYYPlJGF{e2G7		MlPpNUBp	NVXwcXpkTE2VTx?=	MXrhcpRqNUiGQVOxJIFkfGm4aYT5JJdqfGhiSVO1NEBw\iByLkGxNkDPxE1?	MojSNVE6PjB2OEm=
Friend leukemic cell	MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTPOVAh\|ryP	M3u0blczKGh?	MXnEUXNQ	NIrzSVRKSzVyPUCuPVkh\|ryP	M2PPS\|EzOTB7OUGz
K562	M1Xrc2tqdmG\|ZTDBd5NigQ>?		NH23Uo83KGh?	MYXEUXNQ	NGLYfXJKdmirYnn0bY9vKG:oIHj1cYFvKGirc4TvcoUh\GWjY3X0fYxie2ViKH3pfJR2emVib3[gTGRCSzFiYX7kJGhFSUN{KTD3bZRpKEmFNUCgc4YhOC5yMTFOwG0>	NEfnOIEyOjRzOUO4NC=>
HT1080	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXn4NI9[PzJiaB?=	MV;EUXNQ	MWDJR\|UxRTJwNDFOwG0>	MX:xNlI4ODF5NR?=
H1299	MWTLbY5ie2ViQYPzZZk>		MUOyNEBucW5?	NXXBPY9rTE2VTx?=	M1nqR2lvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBJTEGFIHXufplu\SC5aYToJGlEPTBib3[gNE4yQTRizszN	MVmxOFUzOTR{Mh?=
H1299	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXz1UVdbPzJiaB?=	NHTpZWhFVVOR	MYfJR\|UxRTdwMkSg{txO	M{DxZ\|E1PTJzNEKy
HeLa	M2jqUmtqdmG\|ZTDBd5NigQ>?		NHS3Xo0{OCCvaX6=		MVHJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	NUftfHR6OTV4MEO5OFk>
LOX-IMVI	NFXYbFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M33ROVQ5KGh?		NFTRdWhKSzVyPUGuN{DPxE1?	NHP1Um8yPTdzNUS3NC=>
NCI-H226	NHToZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnjOFghcA>?		M3vjOGlEPTB;Mj62JO69VQ>?	NYq4dGkxOTV5MUW0O\|A>
RXF-631L	NVzhXmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Moi1OFghcA>?		MmrrTWM2OD1{IN88US=>	NFjBOGwyPTdzNUS3NC=>
SNB-78	NEjSPHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHG1cIM1QCCq		NVLaVYFZUUN3ME2xOkDPxE1?	NE\zU44yPTdzNUS3NC=>
St-4	NYi5Z\|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4DiNFQ5KGh?		NYG5ZpE{UUN3ME21MlIh\|ryP	MoG1NVU4OTV2N{C=
ARP1	MlGwSpVv[3Srb36gRZN{[Xl?	NGH5NI4zKM7:TR?=	M4fSTVYhcA>?		Mn;1TY5lfWO2aX;uJI9nKFB{MWfBSlEh\2WwZTDlfJBz\XO\|aX;u	Mm\TNVQ4OzR6ME[=
CEM	NHXj[YhMcW6jc3WgRZN{[Xl?		NIm1WmEyKGh?	M3nUNWROW09?	MoWzTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>?	MXixOlQzODB4NB?=
HCT15	M3jscmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPLc2dyPDhiaB?=		NXz5d\|JMT0l3ME2wMlgzKM7:TR?=	MlTDNVY4OjN{Mke=
NCI-H23	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYHpOIdNPDhiaB?=		M3P5UGdKPTB;MD65NkDPxE1?	M2\1PVE3PzJ\|MkK3
GM15850	NHrhbnFMcW6jc3WgRZN{[Xl?	NHfqdHUzNjVizszN	MWO5OkBp	M4LC[mROW09?	NWDQOVdwUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MVmxOlkzOTN4Nx?=
GM15850	NYDUcIxFU2mwYYPlJGF{e2G7	MYSyMlUh\|ryP	M2CzWVk3KGh?	NXPGPGlvTE2VTx?=	NX;YOWlWUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFUh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NGHo[W8yPjl{MUO2Oy=>
GM15850	NHzaXZhMcW6jc3WgRZN{[Xl?	NXjsSll2Oi53IN88US=>	NYrSZ3pLQTZiaB?=	MYfEUXNQ	M3vPcmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTCxNkBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NWPRXpE5OTZ7MkGzOlc>
GM15850	NFvONYxMcW6jc3WgRZN{[Xl?	MWmyMlUh\|ryP	MlvoPVYhcA>?	MVXEUXNQ	NYfzZYVTUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NWLDWG9MOTZ7MkGzOlc>
GM15850	M{TM[2tqdmG\|ZTDBd5NigQ>?	M3nOXlIvPSEQvF2=	M1LFd\|k3KGh?	MV7EUXNQ	M1v6S2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	NFHMfYYyPjl{MUO2Oy=>
GM15850	M3\ldmtqdmG\|ZTDBd5NigQ>?	MmXvNk42KM7:TR?=	NE[5ZYQ6PiCq	NEHqR3ZFVVOR	NULBVnVlUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M{fWdlE3QTJzM{[3
U937	NVfMTVFbTnWwY4Tpc44hSXO\|YYm=	MYW1JO69VQ>?	NWGxbW5lOjRiaB?=	NWK1bmJnTE2VTx?=	NYrYPWlNS2WubDDjfYNt\SCjcoLld5Qh[nliYXPjeY12dGG2aX;uJIF1KFNxR{KvUUBxcGG\|ZR?=	NUj0XnpwOTdyMES3NVg>
H661	M4TDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFXx[Vk1QCCq		NUm3bVdIUUN3ME2xJO69VQ>?	M3KzZ\|E4OTV5MEC5
U937	MoLuSpVv[3Srb36gRZN{[Xl?	Mkj3OUDPxE1?	M2fXelI1KGh?	MkXnSG1UVw>?	Mnq1TY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	Mkf4NVc1PDd5NUC=
U937	M3HNSGZ2dmO2aX;uJGF{e2G7	MlvkNUDPxE1?	MmX3NlQhcA>?	MVrEUXNQ	NXLwTG9VTW[oZXP0JI9vKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44>	NFq0WYsyPzR2N{e1NC=>
RAW264.7	M2L0dmZ2dmO2aX;uJGF{e2G7	MU[xNEDPxE1?	MmHMNlRp	MXr3ZZRmeg>?	MWXJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hf2m2aDDJR\|UxKG:oIECuO\|Yh\|ryP	M4m4blE4PDd5NUG4
RAW264.7	MlTFSpVv[3Srb36gRZN{[Xl?	NInQdWsyOCEQvF2=	NGjr[ZozPGh?	NED5bIV4[XSnch?=	MkD3TY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	NV\hZpdUOTd2N{e1NVg>
SC9	NELhTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MoDJOFghcA>?		M1;id2lEPTB;MD62NFYh\|ryP	NYnEcoh6OTd3MEeyNVk>
ST14A	M4e3bmZ2dmO2aX;uJGF{e2G7	NWKwZnVvPSCwTR?=	NVjmRWt2PzJiaB?=		MojyTY5kemWjc3WgbY4hWkWVVD;OVnNHKG2UTlGg[ZhxemW\|c3nvci=>	M3jl[\|E4PTZ3OUmz
ST14A	NGexOJVHfW6ldHnvckBCe3OjeR?=	M1rrNlUhdk1?	NVXzRpF3PzJiaB?=		NYnySm5kUW6lcnXhd4UhcW5iRULGNUBuWk6DIHX4dJJme3Orb36=	MUWxO\|U3PTl7Mx?=
PANC1	MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\CT\|Eh\|ryP			NX7De5NtUUN3ME2wMlQ2KM7:TR?=	M4Tt[VE4PTh6N{S0
PANC1	NXzwbGh2TnWwY4Tpc44hSXO\|YYm=	MXexJO69VQ>?	NXPlb3oxOjRiaB?=		Mn\ETY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	NH:2fHMyPzV6OEe0OC=>
PANC1	NIjSfFdHfW6ldHnvckBCe3OjeR?=	NF3IcFQyKM7:TR?=	NX3aZpFwOjRiaB?=		NFvHZopKdmO{ZXHz[UBqdiCyMkfrbZAyKGenbnWg[ZhxemW\|c3nvci=>	M17pW\|E4PTh6N{S0
PT45	MlzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHewOo9KSzVyPUSg{txO	MW[xO\|U5QDd2NB?=
ACHN	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{\4fVIyKGh?		MUHHTVUxRTBwNkWg{txO	M3u1cFE4PjZ{NkC2
PC3	M3[1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvH[INLOjFiaB?=		M330UGdKPTB;MD63NUDPxE1?	M{X5[lE4PjZ{NkC2
A431	NYfqRYJsS3m2b4TvfIlkKEG\|c3H5		MVe3NkBp		NF\VTYRKSzVyPUSuNkDPxE1?	NVvmUGNoOTd4OUG3OlM>
Cal27	MXvDfZRwfG:6aXOgRZN{[Xl?		NITSXpY4OiCq		M3ezWGlEPTB;Mz6yJO69VQ>?	M2XlZVE4PjlzN{[z
CCRF-CEM	MnvmR5l1d3SxeHnjJGF{e2G7		NHXSVWQ4OiCq		NWDifIx2UUN3ME2wMlgh\|ryP	NX[xdpdvOTd4OUG3OlM>
EOL1	NWXCOZBzS3m2b4TvfIlkKEG\|c3H5		MUS3NkBp		MoXjTWM2OD1zIN88US=>	MlfDNVc3QTF5NkO=
Hec-1-A	MWrDfZRwfG:6aXOgRZN{[Xl?		M{TnWFczKGh?		MlXETWM2OD1zIN88US=>	Mlj6NVc3QTF5NkO=
HeLa	Mly2T4lv[XOnIFHzd4F6	MYCxNEDPxE1?	M3fUUFMxKG2rbh?=	M2TrUWROW09?	NXjoU25yUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBJTEGFMTD3bZRpKEmFNUCgc4YhOC5yMjFOwG0>	MWGxO\|Y6OTd4Mx?=
RKOp21	NW\vRlVwS3m2b4TvfIlkKEG\|c3H5		NHPLZmU4OiCq		NFfJc3pKSzVyPUGuO\|Yh\|ryP	M2X6SFE4PjlzN{[z
Saos2	NYGwcGRWS3m2b4TvfIlkKEG\|c3H5		MmLCO\|IhcA>?		M{\5T2lEPTB;Mj6zJO69VQ>?	NE\UdoIyPzZ7MUe2Ny=>
SK-OV-3	M1vuemN6fG:2b4jpZ{BCe3OjeR?=		NH3JUXY4OiCq		M1;DW2lEPTB;Mj6yJO69VQ>?	MWOxO\|Y6OTd4Mx?=
U87MG	M{nFRmN6fG:2b4jpZ{BCe3OjeR?=		NGn2bWs4OiCq		M3PQd2lEPTB;MUGg{txO	MVexO\|Y6OTd4Mx?=
NUGC3	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVe1JO69VQ>?	M1\mR\|I1KGh?		M4K3TGdKPTB;Mj63PUDPxE1?	NWP1XFJNOTd7MES4OFM>
CCD1059SK	M3vOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHXRVhiUUN3ME20N{42KM7:TR?=	M2XN[FE5OjR5NUW0
HepG2	MkjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vOV2lEPTB;MD6wNFA3KM7:TR?=	Ml\aNVgzPDd3NUS=
HT1080	NIf3eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU\RR2gxUUN3ME2wMlAxOjRizszN	MnfRNVgzPDd3NUS=
SKBR3	NWW2fo03T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTBwODFOwG0>	NGjv[5UyQDJ2N{W1OC=>
SNB78	NFuxNGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTFR\|UxRTF4IN88US=>	M3jR[FE5OjR5NUW0
SQ20B	NV;VZYdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYe5NJhzUUN3ME2zJO69VQ>?	M13GcVE5OjR5NUW0
St4	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF6zRYVGSzVyPUWuNkDPxE1?	MorXNVgzPDd3NUS=
MCF7	M3m5bGZ2dmO2aX;uJGF{e2G7	NX\ISmo6OTBizszN	MVy4JIg>	MorxSG1UVw>?	Ml:3TY5lfWO2aX;uJI9nKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	MYKxPFI3QTJ{Nh?=
HEK293	MlTnT4lv[XOnIFHzd4F6		MVmxJIg>	NF\3NYtFVVOR	M13HOGlvcGmkaYTpc44hd2ZiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNFMh\|ryP	MWKxPFMxQDV4Mx?=
HEK293	NET5PWtMcW6jc3WgRZN{[Xl?		NGniVIsyKGh?	NH3weXNFVVOR	MXTJcohq[mm2aX;uJI9nKEiGQVOzJJdqfGhiSVO1NEBw\iByLkC1O{DPxE1?	NXq0b4tUOTh\|MEi1OlM>
G401	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{PDW\|czKGh?	MlHzSG1UVw>?	NV;uVGlKUUN3ME2xJO69VQ>?	MYWxPFM4ODN5Mx?=
HeLa	NF;PPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVO3NkBp	M2C2NWROW09?	M3\wbGlEPTB;MD60OkDPxE1?	MoP2NVg{PzB\|N{O=
Human renal epithelial cell	M{P3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUfWW4pmPzJiaB?=	M33P[WROW09?	Mn;sTWM2OD1zNDFOwG0>	NWHoSm85OTh\|N{CzO\|M>
U937	Mn62SpVv[3Srb36gRZN{[Xl?	MmnTOUDPxE1?	NV7Z[2xwOjRiaB?=		MYjJcoR2[3Srb36gc4YhcGm\|dH;u[UBJPCCqeYDldoFk\XS7bHH0bY9v	MWexPFM5OTJ\|OB?=
U937	NH\TcpVHfW6ldHnvckBCe3OjeR?=	M{fTb\|Uh\|ryP	MmjYNlQhcA>?		Ml3ZTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gbJlx\XKjY3X0fYxifGmxbh?=	NG\CVo0yQDN6MUKzPC=>
U937	M{jRNmZ2dmO2aX;uJGF{e2G7	MorhOUDPxE1?	NFrjTFUzPCCq		M4e5[Wlv\HWldHnvckBw\iCyMkGg[ZhxemW\|c3nvci=>	NYDwSlU1OTh\|OEGyN\|g>
U937	M2X0SmZ2dmO2aX;uJGF{e2G7	MnLBOUDPxE1?	MYSyOEBp		MUnJcoR2[3Srb36gc4Yh[XCxcITvd4l{	NHLhN3gyQDN6MUKzPC=>
U937	NGO5eWRHfW6ldHnvckBCe3OjeR?=	MmXaOUDPxE1?	NVnxb5hHOjRiaB?=		NHLhTJlKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=	MlzQNVg{QDF{M{i=
U937	M4fRd2tqdmG\|ZTDBd5NigQ>?	MUC1JO69VQ>?	M4LpNFI1KGh?		M3vXc2lvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{G=	NFvpeokyQDN6MUKzPC=>
U937	Mm\YT4lv[XOnIFHzd4F6	NUHzeGxUPSEQvF2=	NIXqUJAzPCCq		NWXTfXBpUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	MXOxPFM5OTJ\|OB?=
HEK-TE	MofKSpVv[3Srb36gRZN{[Xl?	NEfPc\|M2KM7:TR?=	MXW2bC=>	MWTEUXNQ	MlziTY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	MYexPFQ{PDF2NB?=
HPDE6c7	NG[zeXlEgXSxdH;4bYMhSXO\|YYm=	NWHLZ21XPTBizszN	NFPTPJY4OiCq	MVHEUXNQ	NGrET2lKSzVyPUGuN{DPxE1?	NYTGNGRIOTh2OUS0OlM>
Human microvascular epithelial cell	NHvyelVEgXSxdH;4bYMhSXO\|YYm=	M3PCWlUxKM7:TR?=	MYe3NkBp	MXHEUXNQ	NEezSJlKSzVyPUGuN{DPxE1?	M4HvWlE5PDl2NE[z
Hup T3	NXTpO2JIS3m2b4TvfIlkKEG\|c3H5	NHPDOFU2OCEQvF2=	Mmr6O\|Jp	M1u1TmROW09?	MXHJR\|UxRTBwODFOwG0>	NUjINZpiOTh2OUS0OlM>
Mia Paca2	NHzlWZREgXSxdH;4bYMhSXO\|YYm=	M{fmd\|UxKM7:TR?=	NXT1fYZuPzKq	MVPEUXNQ	NIHreY1KSzVyPUGuNUDPxE1?	NXHpUIJSOTh2OUS0OlM>
Panc 04.03	M2jveWN6fG:2b4jpZ{BCe3OjeR?=	M1foNlUxKM7:TR?=	MljHO\|Jp	NIDUOFlFVVOR	NX7ST2VoUUN3ME2xMlIh\|ryP	M4n0WlE5PDl2NE[z
SU 86.86	MVXDfZRwfG:6aXOgRZN{[Xl?	M3\RbVUxKM7:TR?=	MorTO\|Jp	NFnDdYJFVVOR	MlS5TWM2OD1zLkOg{txO	M1TYXFE5PDl2NE[z
HEK293	Mli2T4lv[XOnIFHzd4F6		M{PVdVMhcA>?		M1XINWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzZiZYjwdoV{e2mxbjD3bZRpKEmFNUCgc4YhOC5yMUmg{txO	M3j4e\|E5PTV6Nk[5
HeLa	NVf6OHRPU2mwYYPlJGF{e2G7		NW\rSohPOiCq		NVHYW4lpUW6qaXLpeIlwdiCxZjDueYNt\WG{IFjERWMhf2m2aDDJR\|UxKG:oIECuNFg{KM7:TR?=	NUjWXVdjOTh3NUi2Olk>
RAW264.7	MkXWSpVv[3Srb36gRZN{[Xl?	NUXz[mhuOiEQvF2=	MXSzMlUhcA>?	MknOSG1UVw>?	NVexc2ptSW62aX3hcIFzcWGuIHHjeIl3cXS7IHHnZYlve3RiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJIlv\mWldHXkJJdqfGhiSVO1NEBw\iByLkGxJO69VQ>?	NX;kXWtvOTh4NES5Olk>
NB4			MmDLOFhp	MonsSG1UVw>?	M1jnS2lEPTB;MD62JO69VQ>?	MVWxPFczOzN2OR?=
HEK293	MmrjSpVv[3Srb36gRZN{[Xl?	NV3l[2pMOTBizszN	NIrxeZMzPCCq	Ml\NSG1UVw>?	M3uyVmFkfGm4YYTpc44hd2ZibX;1d4UhX262M3Ggd4lodmGuaX7nJIV5eHKnc4Pl[C=>	MmT1NVkxOjJ4N{W=
HCT116	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFHDbJg4Omh?	MX7EUXNQ	M4TLVWlEPTB;MD6zNUDPxE1?	MWixPVA5PDJ7NB?=
HeLa	Moe2T4lv[XOnIFHzd4F6	MVyyJO69VQ>?	NXjKbldxOzBibXnu	M3PENWROW09?	MkCzTY5pcWKrdHnvckBw\iCKRFHDNkBqdiCqdX3hckBJ\UyjIHPlcIx{KHerdHigTWM2OCCxZjCwMlEh\|ryP	MYqxPVA5PDJ7NB?=
IGROV1	NEjSN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NFznOIs4OiCq	NVTVbpptTE2VTx?=	NX3ydGh1UUN3ME2yMlIh\|ryP	MlXENVkxQDR{OUS=
IGROV1	M1nxVGtqdmG\|ZTDBd5NigQ>?	M336ZVUh\|ryP	M{jwWVI1KGh?	MmDGSG1UVw>?	MUfJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMheDV\|IHHj[ZR6dGG2aX;u	M1rqeVE6ODh2Mkm0
IGROV1	MWXLbY5ie2ViQYPzZZk>	MYmxNEDPxE1?	MXy0JIg>	NH7x[GtFVVOR	NI\1S3pKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	MkT1NVkxQDR{OUS=
IGROV1	MVTLbY5ie2ViQYPzZZk>	M1nQdFExKM7:TR?=	MWO0JIg>	MUfEUXNQ	MWLJcohq[mm2aX;uJI9nKEiGQVO2JIF{e2W\|c3XkJIF{KGGucHjhMZR2[nWuaX6gZYNmfHmuYYTpc44>	NFPqcoQyQTB6NEK5OC=>
T24	MlrvT4lv[XOnIFHzd4F6		MVezJIg>		M3mxN2lv\HWldHnvckBw\iCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGyJO69VQ>?	NH3DRZMyQTB6NEO5OS=>
T24	NF;2NHJMcW6jc3WgRZN{[Xl?		NHK1cpQ{KGh?		M2TVUWlv\HWldHnvckBw\iCjbIDoZUB1fWK3bHnuJIFk\XS7bHH0bY9vKHerdHigSWM2OCCxZjCwMlI2KM7:TR?=	MkW0NVkxQDR\|OUW=
HeLa	NEPGRWNMcW6jc3WgRZN{[Xl?		M{fySlE2KG2rbh?=	MmPzSG1UVw>?	M2D3RWlvcGmkaYTpc44hd2ZiSFTBR\|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>	M3iyUFE6ODl\|OEi0
HeLa	MXLLbY5ie2ViQYPzZZk>		NGOzUpMyPSCvaX6=	M1jZWGROW09?	NVvLWXN4UW6qaXLpeIlwdiCxZjDISGFEQCCocn;tJI52[2ynYYKg[Zh1emGldDD3bZRpKEmFNUCgc4YhOS56NjFOwG0>	NVr6bVh2OTlyOUO4PFQ>
NCI-H69	NX:zN2Y4S3m2b4TvfIlkKEG\|c3H5		MoHzO\|IhcA>?	Mn[wSG1UVw>?	NFm3U4ZKSzVyPUKuNFYh\|ryP	MXexPVA6Ozh6NB?=
SKMES1	MnnuR5l1d3SxeHnjJGF{e2G7		M2LQfFczKGh?	MWTEUXNQ	M1LyNGlEPTB;Mj60NkDPxE1?	M3\IdVE6ODl\|OEi0
S2	NXrsbJZtU2mwYYPlJGF{e2G7	M3L1eFAvOS1zMDFOwG0>	NFfJT28yKGh?		NXjUW3pvUW6qaXLpeIlwdiCxZjDQcIF{dW:maYXtJIZidGOrcHHyeY0hUESDQ{Gg[ZhxemW\|c3XkJJdqfGhiSVO1NEBw\iByLkC1PUDPxE1?	Ml7jNVk{OTd2NUC=
SHSY5Y	MljLT4lv[XOnIFHzd4F6	NXnrUo9POTBizszN	MoPvOFghcA>?	NXzOWHJuTE2VTx?=	NF7kPYNKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOUDPxE1?	MYCxPVM1PDF5NR?=
SHSY5Y	Moe4R5l1d3SxeHnjJGF{e2G7	MXuxNEDPxE1?	MnHqOFghcA>?	M3LK[mROW09?	MX7JR\|UxRTJizszN	MXyxPVM1PDF5NR?=
DMS114	NXfwXGp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2rXcFQ5KGh?		MnXQS2k2OD1{Lkmg{txO	MYKxPVQyQTJyNR?=
HBC5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvuOFghcA>?		MWrHTVUxRTF5IN88US=>	NEDQN2IyQTRzOUKwOS=>
SNB78	M4GzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGXHRZE1QCCq		NEi2VXBIUTVyPUG2JO69VQ>?	M4fD[VE6PDF7MkC1
HeLa	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEXGTlQ4OiCq	NY\iRmlFTE2VTx?=	NVXxeYxSUUN3ME2wMlQ3KM7:TR?=	MoLBNVk1PDF6NE[=
BHK	MnH1T4lv[XOnIFHzd4F6	MmLLOUDPxE1?	M1rsUVI1KGh?	NFjsTYlFVVOR	M1:1dWlvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	MoDwNVk6PjZ5OEm=
CFBE41o-	Mn7mT4lv[XOnIFHzd4F6	NHTnWnU2KM7:TR?=	MUm4JIg>	MkT5SG1UVw>?	NYX2SWFWUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	NFPhZ4EyQTl4Nke4PS=>
CFBE41o-	M{\PU2tqdmG\|ZTDBd5NigQ>?	MoT1OUDPxE1?	MmLXOEBp	MnHtSG1UVw>?	NFTyUIVKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hdGW4ZXy=	NY\3SG1TOTl7Nk[3PFk>
CFBE41o-	MYPLbY5ie2ViQYPzZZk>	MXmxJO69VQ>?	NEK0dHMyKGh?	NHH1c29FVVOR	MkLwTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIFPGWHIheHKxdHXpckBt\X[nbB?=	MlnONVk6PjZ5OEm=
Primary bronchial epithelial cell	MljCT4lv[XOnIFHzd4F6	MorMNUDPxE1?	MnjrNlQhcA>?	NVuyTYVJTE2VTx?=	MofCTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gcZV1[W62IF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4h[XCrY3HsJJN2em[jY3WgcI9k[WyrenH0bY9v	M1LnXlE6QTZ4N{i5
CFBE41o-	NIfLPXRMcW6jc3WgRZN{[Xl?	MVqxJO69VQ>?	MXS1JIRigXN?	MW\EUXNQ	MVrJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIP0ZYJqdGm8YYTpc44hd2ZiRnTlcJRiPTB6IFPGWHIheHKxdHXpci=>	MnP6NVk6PjZ5OEm=
CFBE41o-	M3\YbmtqdmG\|ZTDBd5NigQ>?	MYexJO69VQ>?	MmrpNlQhcA>?	M4j4[GROW09?	MYDJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIF\k[Yx1[TVyODDDSnRTKHC{b4TlbY4hfHKjZn\pZ4tqdmd?	NWH1eFZCOTl7Nk[3PFk>
CFBE41o-	MWjLbY5ie2ViQYPzZZk>	MVu1JO69VQ>?	Mny2NlQhcA>?	MUHEUXNQ	NFLuR3BKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJJifGVib3[gcYF1fXKjdHnvckBw\iCFRmTSJJBzd3SnaX6geI8hcXS\|IHfsfYNw\m:{bR?=	NHmx[nIyQTl4Nke4PS=>
CFBE41o-	MX7LbY5ie2ViQYPzZZk>	NWX0dI9HPSEQvF2=	M4nmeVI1KGh?	M2fDS2ROW09?	MnrKTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrdImgc4YhTmSnbIThOVA5KEOIVGKgdJJwfGWrbh?=	MmezNVk6PjZ5OEm=
CFBE41o-	NGPLUZRMcW6jc3WgRZN{[Xl?	M2i1OlUh\|ryP	Mn;HNlQhcA>?	MXfEUXNQ	NYXNOVA5UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDjc5Jz\WO2aX;uJI9nKG23dHHueEBH\GWudHG1NFghS0[WUjD0doFn\mmla3nu[{B1dyClZXzsJJN2em[jY3WgZZMh\2y7Y3;mc5Ju	NXP4XnlTOTl7Nk[3PFk>
Primary bronchial epithelial cell	MYHLbY5ie2ViQYPzZZk>	M16xfVUh\|ryP	NXHINI5ROjRiaB?=	MWLEUXNQ	MoDhTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDteZRidnRiRnTlcJRiPTB6IFPGWHIheHKxdHXpckBieGmlYXygd5Vz\mGlZTDsc4NidGm8YYTpc44>	NHu0U3IyQTl4Nke4PS=>
Primary bronchial epithelial cell	MXnLbY5ie2ViQYPzZZk>	Ml;CNUDPxE1?	NEXQN5E6PiCq	MoDuSG1UVw>?	MUHJcohq[mm2aX;uJI9nKEiGQVO3JIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIPoc5J1KGOrcnP1bZQh[3W{cnXueJM>	NUjjSnQ1OTl7Nk[3PFk>
BxPC3	M1\yXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4fkZlczKGh?		Mn;kTWM2OD1{Lkeg{txO	MV[yNFE1Ozd5OB?=
CAL27	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml[wO\|IhcA>?		Mk\DTWM2OD1\|LkeyJO69VQ>?	Ml24NlAyPDN5N{i=
Capan1	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGLtOnk4OiCq		MnnQTWM2OD15LkOg{txO	MV6yNFE1Ozd5OB?=
HCC827	M1LJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NYTm[nNWPzJiaB?=		NFT6dlFKSzVyPUGuPEDPxE1?	M4jFUlIxOTR\|N{e4
LNCAP	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGT5bnE4OiCq		M3zGNmlEPTB;MD61PEDPxE1?	MlTGNlAyPDN5N{i=
NCI-H2122	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWC3NkBp		NYLmdXNVUUN3ME23MlUh\|ryP	NFro[ZUzODF2M{e3PC=>
NCI-H358	M{HER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXXjeo4{PzJiaB?=		MmK0TWM2OD1{LkWg{txO	M365bVIxOTR\|N{e4
SCC15	NHfZWHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkDTO\|IhcA>?		NFzaU5NKSzVyPUKuOFkh\|ryP	MWeyNFE1Ozd5OB?=
SCC25	MnXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEjz[Iw4OiCq		MX\JR\|UxRTFwOUOg{txO	MlrtNlAyPDN5N{i=
SKHEP1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVf3bXNWPzJiaB?=		NXvHWGl6UUN3ME2zMlQ3KM7:TR?=	NGL0S3gzODF2M{e3PC=>
BJ	NYrDS5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVSxNFAh\|ryP	MXW0PEBp	MXnEUXNQ	M3Tl[2dzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	MlPRNlAyPDN6NEC=
MUF	NH:wSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;kS4EyODBizszN	NGXjUnc1QCCq	MVPEUXNQ	NWPFPXhzT3Kxd4ToJIlvcGmkaYTpc44h[XRiMD6wOUB1dyBzMECgeW0>	M{[3N\|IxOTR\|OESw
Caco-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn;vNVAxKM7:TR?=	NXzEcYp6PDiq	M3fr[GROW09?	NU\sUYNsUUN3ME24MlEh\|ryP	NH7ZfHAzODF2M{i0NC=>
Caco-2	M1W2eWtqdmG\|ZTDBd5NigQ>?	NVzJU5I6PSEQvF2=	MWK0JIg>	MnzGSG1UVw>?	M2LsNmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgZYNmfHmuYYTpc44hUUN3MDDv[kAxNjB\|NzFOwG0>	MWqyNFE1Ozh2MB?=
Caco-2	M4XaN2tqdmG\|ZTDBd5NigQ>?	NXLzT2hFOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	NVLnT5hMPCCq	NVy4Z2FyTE2VTx?=	NGjHZVdGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NVHkUFNYOjBzNEO4OFA>
Caco-2	NIjkPVdMcW6jc3WgRZN{[Xl?	NFnwcnQxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	MlrHOEBp	NEntcIdFVVOR	MlPHSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	Ml;VNlAyPDN6NEC=
Caco-2	MX3LbY5ie2ViQYPzZZk>	NIL0OWE3NjN{IH7NJJRwKDZ\|MjFOwG0>	MWW0JIg>	MlfySG1UVw>?	MmDkSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN3IIfpeIghUUN3MDDv[kAyOi54IN88US=>	M4jnfVIxOTR\|OESw
Caco-2	NWTHfYZPU2mwYYPlJGF{e2G7	NVSzc\|RkPi5\|MjDuUUB1dyB4M{Kg{txO	NWK1W4FmPCCq	NF7ofW1FVVOR	MVvFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzdid3n0bEBKSzVyIH;mJFQyKM7:TR?=	M{\YTFIxOTR\|OESw
Caco-2	NV\3SnREU2mwYYPlJGF{e2G7	NXy2fJpSOC5\|MU[gcm0hfG9iM{GuOkDPxE1?	M4fT[FQhcA>?	MYDEUXNQ	MX7FfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ?	MYqyNFE1Ozh2MB?=
HepG2	Mo\4T4lv[XOnIFHzd4F6	MlHzOUDPxE1?	MkDFOog>	MYXEUXNQ	MYnJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	NHP0fZQzODF2M{i0NC=>
HepG2	NXfuVJlIU2mwYYPlJGF{e2G7	MXq1JO69VQ>?	NHj0clg3cA>?	MoT5SG1UVw>?	NXOyPFFFUW6mdXP0bY9vKG:oIFjERWMudWWmaXH0[YQhcGm\|dH;u[UBpgXCncnHj[ZR6dGG2aX;u	M{DjbFIxOTR\|OESw
HepG2	NXXsTW9MU2mwYYPlJGF{e2G7	NEfSZoU2KM7:TR?=	MVK2bC=>	M4riSWROW09?	MXPJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	NWTI[mM3OjBzNEO4OFA>
HepG2	NGD2UJRMcW6jc3WgRZN{[Xl?	M3j5N\|Uh\|ryP	M{DsRVZp	NHToZoNFVVOR	MorTTY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgTFMwUDRiaHnzeI9v\SCjY3X0fYxifGmxbh?=	NXO4VoJoOjBzNEO4OFA>
COLO205	NGO1[WhMcW6jc3WgRZN{[Xl?	NX[zXWxIOTBizszN	MXKyOEBp	MVHEUXNQ	NVrrfXkzUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJOyCjY3X0fYxifGmxbjD3bZRpKEmFNUCgc4YhOi5{IN88US=>	NELmSYwzODR3MUO3PC=>
SCC4	MXjLbY5ie2ViQYPzZZk>	MVOxJO69VQ>?	M4jjXFI1cA>?		Mn\iTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	M3f0VlIxPDV{MkK1
SCC4	NUTySpR{U2mwYYPlJGF{e2G7	M3juVVEh\|ryP	M4H0flI1cA>?		NWjKOWZUUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgZYNmfHmuYYTpc44>	NEPKbG4zODR3MkKyOS=>
SCC4	MWPGeY5kfGmxbjDBd5NigQ>?	NFPSNZIyKM7:TR?=	NXHo[ndqPSCvaX6=		MoHKRYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	MWKyNFQ2OjJ{NR?=
NB4	MnW4SpVv[3Srb36gRZN{[Xl?	NU\Qb2FsPSEQvF2=	NXfEXmtCOjRiaB?=	M1nvTWROW09?	NE\iTXdE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	NYTRenF7OjB2OUG0OFA>
NB4	NXrwWHdpU2mwYYPlJGF{e2G7	NH\aXXg2KM7:TR?=	MmHlNlQhcA>?	Mo\kSG1UVw>?	MYPJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iYXPleJlt[XSnIIT1ZpVtcW5ibHX2[Yw>	MVWyNFQ6OTR2MB?=
NB4	Ml[0SpVv[3Srb36gRZN{[Xl?	M2rjXFUh\|ryP	M2\ZeVI1KGh?	MYnEUXNQ	MlK1TY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;u	NVnBT2tCOjB2OUG0OFA>
NB4	NH\xV5VMcW6jc3WgRZN{[Xl?	MlXQOUDPxE1?	NV30Too2OjRiaB?=	MWrEUXNQ	M3XJUmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v	MYmyNFQ6OTR2MB?=
NUGC3	NIrLZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rFSmdKPTB;Mj65OEDPxE1?	M2fhVlIxQDVyOUex
A549	MXXGeY5kfGmxbjDBd5NigQ>?	MVS1JO69VQ>?	NFHqc4c{KGh?	MUTEUXNQ	M1ewWGlv\HWldHnvckBw\iCjdYTvdIhi\3liaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCOQ{PJTS=>	M1jmWVIxQDV3MkC4
HUT78	M1fGTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MU[3NkBp	NVqxfm97TE2VTx?=	NUW4WVU{T0l3ME2wMlMh\|ryP	MYOyNFg5PDJyOB?=
U937	NXuybY1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGXqVGU4OiCq	MULEUXNQ	Mn3MS2k2OD1yLkO5JO69VQ>?	NFzIfFQzODh6NEKwPC=>
A431	M4ni[GN6fG:2b4jpZ{BCe3OjeR?=		MmjhO\|IhcA>?		NIrK[I5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPDNzIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGVITlJid3n0bEBKSzVyIH;mJFQvOiEQvF2=	MV:yNVA5ODZ{OR?=
A549	MYXDfZRwfG:6aXOgRZN{[Xl?		NEL3WJg4OiCq		NHHhd25EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvQCEQvF2=	NHXLeGszOTB6ME[yPS=>
CAL27	NVjFW\|ZtS3m2b4TvfIlkKEG\|c3H5		M3jWU\|czKGh?		MVvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDRWwzPyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjCzMlIh\|ryP	MUKyNVA5ODZ{OR?=
HeLa	MnTPR5l1d3SxeHnjJGF{e2G7		NWrDZVlbPzJiaB?=		M2ru[mN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmVGFiY3XscJMhd3[ncnX4dJJme3OrbnegTGRCSyC5aYToJGlEPTBib3[gNU42KM7:TR?=	NYrmc3B5OjFyOEC2Nlk>
Sf21	NH30UG5McW6jc3WgRZN{[Xl?		M2\CZ\|MhcA>?		NU\WOVM3UW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	MkDzNlExQDB4Mkm=
SKBR3	MVfDfZRwfG:6aXOgRZN{[Xl?		NYDkZVR7PzJiaB?=		MmXsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tDWjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk43KM7:TR?=	MmfNNlExQDB4Mkm=
SKOV3	NI\IOldEgXSxdH;4bYMhSXO\|YYm=		NY[ySZpKPzJiaB?=		MXvDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT29XOyClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISXIzKHerdHigTWM2OCCxZjCyMlIh\|ryP	MoTzNlExQDB4Mkm=
COR-L23	M4flcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\HNVAh\|ryP	MYi3NkBp	NWTZV\|kyTE2VTx?=	MUTHTVUxRTFwMTFOwG0>	MnjTNlExQDB4NEe=
DU145	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWmxNEDPxE1?	MXS3NkBp	M3rPTmROW09?	MX7HTVUxRTFwMEWg{txO	MkfONlExQDB4NEe=
LoVo	M4jQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\hb3MyOCEQvF2=	MWm3NkBp	NFzR[3BFVVOR	M3mzc2dKPTB;MT63JO69VQ>?	M2WwSlIyODhyNkS3
MCR5-SV2	M4HrWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVywemRZOTBizszN	M4LTV\|czKGh?	MoHjSG1UVw>?	M1TUbWdKPTB;Mj6xJO69VQ>?	M4PqZ\|IyODhyNkS3
HCT116	MVvLbY5ie2ViQYPzZZk>	MXqzNEDPxE1?	NXXTfGxlOzBiaB?=	MX7EUXNQ	Mo\4TY5pcWKrdHnvckBw\iCKRFHDOkBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gZYxxcGFvdIXieYxqdiCjY3X0fYxifGmxbh?=	NEn5fnQzOTB6ME[0Oy=>
HCT116	NWKzZVB{U2mwYYPlJGF{e2G7	MojNN\|Ah\|ryP	NX;pZZJwOzBiaB?=	M3Xy[2ROW09?	Ml\QTY5pcWKrdHnvckBw\iCKRFHDNUBie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gbIl{fG:wZTDIN2s6KGGlZYT5cIF1cW:w	M3LTW\|IyODhyNkS3
U937	NFHYO5dMcW6jc3WgRZN{[Xl?	MYG1JO69VQ>?	NWHzWZM2OjRiaB?=	MXXEUXNQ	MXHJcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SCKMzDheEBMQQ>?	Mmq2NlEzQTJ2OUK=
U937	Mk\YT4lv[XOnIFHzd4F6	MXi1JO69VQ>?	M3WxTVI1KGh?	MY\EUXNQ	NYXm[WFnUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	MYGyNVI6OjR7Mh?=
U937	MYfLbY5ie2ViQYPzZZk>	MWS1JO69VQ>?	Ml65NlQhcA>?	NVnRXXlRTE2VTx?=	M371fGlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBx[W5vYXPleJlt[XSnZDDobZN1d26nIFi0JIxmfmWu	MWGyNVI6OjR7Mh?=
U937	MX3LbY5ie2ViQYPzZZk>	NEHQbYQ2KM7:TR?=	M3fmdFE2KG2rbh?=	M4DnVWROW09?	MW\Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gbIl{fG:wZTDIN{Bi[2W2eXzheIlwdiCuZY\lcC=>	NEnadYkzOTJ7MkS5Ni=>
A2780	NYPBcXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFnTSpE6PiCq	NEizd3JFVVOR	MmrnTWM2OD1zLk[yJO69VQ>?	NWLrRlR7OjF4M{S0N\|A>
COLO205	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MnXqPVYhcA>?	Mk\nSG1UVw>?	MoTBTWM2OD1{LkGyJO69VQ>?	NYDQSJVFOjF4M{S0N\|A>
Hep3B	MoHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYr3ZWtUPDhiaB?=	NIjxUWhFVVOR	MWnHTVUxRTFwMkGg{txO	M3LBSlIyPzF{MUS2
GM11272	M4LzVWZ2dmO2aX;uJGF{e2G7	NWnwTYpuOTByIH7N	MlXsO\|IhcA>?	NUKyWFExTE2VTx?=	MX7S[YFkfGm4YYTpc44hd2ZiTXXDdFIhdXW2YX70JIV5eHKnc4Ppc44h[XRiMUCgeI8hOTByIH7N	Mnn6NlE5PDB5MU[=
CFBE41o	NV;WcmxrU2mwYYPlJGF{e2G7	M2Lre\|Uh\|ryP		NF7pd5RFVVOR	MkjqSI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVO	MVuyNVk5PDl3OB?=
CFBE41o	NFP1elFHfW6ldHnvckBCe3OjeR?=	M{Hxe\|Eh\|ryP	NYPBfHljOjRiaB?=	MWnEUXNQ	MlH4VoV{fG:{YYTpc44hd2ZiQ1\UVkBl\Wy2YV[1NFghdXW2YX70JJRz[W[oaXPrbY5oKHSxIHPlcIwhe3W{ZnHj[UBieyCpbInjc4Zwem2\|	M2[2cVIyQTh2OUW4
DU145	MWDLbY5ie2ViQYPzZZk>	M2\UNVIvPSEQvF2=	MkfQNlQhcA>?	NWjsVo45TE2VTx?=	M1znXmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YheDJzd3HmNUBxem:2ZXnuJIV5eHKnc4Ppc44>	M2LvZ\|IzOjZyMU[2
DU145	NHLibYxMcW6jc3WgRZN{[Xl?	MoTQOUDPxE1?	M1PMXFI1KGh?	MXrEUXNQ	NGfQTZBKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\SCKNDDhZ4V1gWyjdHnvci=>	M4TGelIzOjZyMU[2
DU145	NYjVeHRqU2mwYYPlJGF{e2G7	NUDESHdQPSEQvF2=	MWSyOEBp	M1Gx[mROW09?	NWmyfI1HUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?=	MnLCNlIzPjBzNk[=
786-0	M4XZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XaNlYvOiEQvF2=	NWCyOIVTPzJiaB?=	MYLEUXNQ	MVTHTVUxRTNwMjFOwG0>	NF\CeIMzOjR\|NU[2PS=>
A498	M4jPWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3zOk4zKM7:TR?=	NHnRUJk4OiCq	Mom5SG1UVw>?	NVjlRllQT0l3ME2xMlYh\|ryP	NYrSOFc{OjJ2M{W2Olk>
A549/ATCC	M3HmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWC2MlIh\|ryP	NFfuWIw4OiCq	NYPsfII3TE2VTx?=	NWq1dZpTT0l3ME2xMlYh\|ryP	NYm3[4NmOjJ2M{W2Olk>
ACHN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGi0eII3NjJizszN	M2fnOVczKGh?	NUjmXXdZTE2VTx?=	M2P2OmdKPTB;MT6zJO69VQ>?	NHX3dJgzOjR\|NU[2PS=>
BT549	NXPQe4pqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPCOk4zKM7:TR?=	MkjoO\|IhcA>?	NED4PHdFVVOR	MUnHTVUxRTFwMzFOwG0>	NVzTPFVjOjJ2M{W2Olk>
EKVX	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLtZ\|BVPi5{IN88US=>	MnPSO\|IhcA>?	M1G0bmROW09?	Mn3kS2k2OD1zLkOg{txO	NX31VIZ6OjJ2M{W2Olk>
HCT15	NHrJcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3NOk4zKM7:TR?=	M{f5WFczKGh?	MYfEUXNQ	MWTHTVUxRTJwNTFOwG0>	NEjKS5UzOjR\|NU[2PS=>
HOP92	NWD0do1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjmOk4zKM7:TR?=	M{LhcVczKGh?	NHHjfVdFVVOR	NHflcndIUTVyPUSg{txO	NIrER2ozOjR\|NU[2PS=>
IGROV1	NGDqNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\KOk4zKM7:TR?=	MXy3NkBp	MUnEUXNQ	NHO3NFRIUTVyPUGuN{DPxE1?	M2H0TVIzPDN3Nk[5
LOXIMVI	NWTtV2lET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33yXFYvOiEQvF2=	MnLNO\|IhcA>?	MorjSG1UVw>?	M4fKOGdKPTB;MTFOwG0>	Ml\4NlI1OzV4Nkm=
M14	MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTmVXE3NjJizszN	NUPYbmxnPzJiaB?=	MmPoSG1UVw>?	NYPSdIhsT0l3ME2xMlMh\|ryP	NYHzUFMzOjJ2M{W2Olk>
MALME-3M	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;rU5Y3NjJizszN	NWnnVpRHPzJiaB?=	NGLl[2tFVVOR	MnHMS2k2OD1yLkOyJO69VQ>?	MonLNlI1OzV4Nkm=
MCF10A	MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVW2MlIh\|ryP	MlzaOFghcA>?	MkjnSG1UVw>?	MYjHTVUxRTlwNjFOwG0>	NYjLS2J5OjJ2M{W2Olk>
MDA-MB-435	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4G4dlYvOiEQvF2=	NYezVYQ{PzJiaB?=	MUnEUXNQ	MnjWS2k2OD1yLkWg{txO	M3XmU\|IzPDN3Nk[5
MDA-MB-468	M{HhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7sUG5jPi5{IN88US=>	NEW4Wok4OiCq	MWnEUXNQ	M3rZS2dKPTB;MD62N{DPxE1?	MonvNlI1OzV4Nkm=
MOLT4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fKd\|YvOiEQvF2=	MXu3NkBp	NIPDVVNFVVOR	MYDHTVUxRTBwNDFOwG0>	M3LueVIzPDN3Nk[5
NCI-ADR-RES	NYHPSmlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYS2MlIh\|ryP	NYL3[WpoPzJiaB?=	NGjYT2hFVVOR	NVn5ZopwT0l3ME2wMlE3KM7:TR?=	M2jLe\|IzPDN3Nk[5
NCI-H23	NH61WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXEOk4zKM7:TR?=	Mn;GO\|IhcA>?	MnrrSG1UVw>?	NHXmeI9IUTVyPUGg{txO	M2\wTlIzPDN3Nk[5
NCI-H322M	MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVO2MlIh\|ryP	MXO3NkBp	NFHQRmpFVVOR	NEPRPFlIUTVyPUCuO\|kh\|ryP	MkfLNlI1OzV4Nkm=
NCI-H460	NVjMfWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHP4cIQ3NjJizszN	MkH4O\|IhcA>?	MWPEUXNQ	NHzXdpBIUTVyPUCuO\|kh\|ryP	M33LcFIzPDN3Nk[5
NCI-H522	NIDDSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmK5Ok4zKM7:TR?=	M3ezZ\|czKGh?	Mn;rSG1UVw>?	NEPXPI5IUTVyPUCuOUDPxE1?	NX3HVWhzOjJ2M{W2Olk>
OVCAR3	NWDESo5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3e1OlYvOiEQvF2=	NX64Z3h{PzJiaB?=	M{jIWmROW09?	MkTJS2k2OD1zLkOg{txO	MUSyNlQ{PTZ4OR?=
OVCAR4	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGW0bmg3NjJizszN	M1PmXVczKGh?	MmjrSG1UVw>?	M2DoRWdKPTB;NDFOwG0>	NXXqSXgzOjJ2M{W2Olk>
OVCAR5	NX3YcWZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXW2MlIh\|ryP	NF75N3k4OiCq	M1[4T2ROW09?	Mn;QS2k2OD1yLke5JO69VQ>?	NF7BVIkzOjR\|NU[2PS=>
OVCAR8	M{HQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHzOk4zKM7:TR?=	NXPGflNXPzJiaB?=	NHqxWYhFVVOR	NInjZoNIUTVyPUCuOUDPxE1?	M3v6bVIzPDN3Nk[5
RXF393	NXX0WXd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3WzXFYvOiEQvF2=	MVK3NkBp	MUXEUXNQ	NV3HcHlmT0l3ME2xMlMh\|ryP	MX:yNlQ{PTZ4OR?=
SF268	NX;OToFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVe2MlIh\|ryP	NIm3dFc4OiCq	MoL2SG1UVw>?	NIXhVoRIUTVyPUGuOkDPxE1?	MUWyNlQ{PTZ4OR?=
SF295	NUe0epR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWi2MlIh\|ryP	NUf6UohrPzJiaB?=	M3X0T2ROW09?	MoXYS2k2OD1zLk[g{txO	NXHDW4ZKOjJ2M{W2Olk>
SF539	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHHUpY3NjJizszN	NWrV[2R[PzJiaB?=	MnHPSG1UVw>?	MYjHTVUxRTJizszN	M4LCSlIzPDN3Nk[5
SK-MEL-2	Mn7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYS2MlIh\|ryP	NUn1OId1PzJiaB?=	MYDEUXNQ	NFSzdFBIUTVyPUGuN{DPxE1?	MkC1NlI1OzV4Nkm=
SK-MEL-28	MojMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYK2MlIh\|ryP	NIfHNXA4OiCq	NHz5cVFFVVOR	NVHRVlY4T0l3ME2xJO69VQ>?	NWjCb45iOjJ2M{W2Olk>
SK-MEL-5	MmX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4OwUlYvOiEQvF2=	MoTlO\|IhcA>?	M4PubWROW09?	M3nz[WdKPTB;MD62N{DPxE1?	MXqyNlQ{PTZ4OR?=
SKOV3	M2rFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfLOk4zKM7:TR?=	NIDGb4M4OiCq	MoTvSG1UVw>?	M{HZZ2dKPTB;MTFOwG0>	NY\aeZVUOjJ2M{W2Olk>
SN12C	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;IS2c3NjJizszN	MVS3NkBp	NWrOXJN1TE2VTx?=	M3zRWWdKPTB;MjFOwG0>	M1Lye\|IzPDN3Nk[5
SNB19	M1P0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlj6Ok4zKM7:TR?=	MlXXO\|IhcA>?	MUTEUXNQ	MlW2S2k2OD1yLk[zJO69VQ>?	M4DSOFIzPDN3Nk[5
SNB75	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYe2MlIh\|ryP	MnLZO\|IhcA>?	MVTEUXNQ	Mn[3S2k2OD1yLke5JO69VQ>?	MkXzNlI1OzV4Nkm=
SR	NV;hTnRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWq2MlIh\|ryP	NGTFb5Y4OiCq	NFXyOYNFVVOR	MYjHTVUxRTBwNDFOwG0>	NULLdlA5OjJ2M{W2Olk>
T47D	NIXBVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkK5Ok4zKM7:TR?=	MWO3NkBp	M3\GfmROW09?	MnS1S2k2OD1yLkWg{txO	NFnjN3IzOjR\|NU[2PS=>
TK10	NXS4S2FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLMOk4zKM7:TR?=	NH\DZ2I4OiCq	M2TofGROW09?	NH\zNJJIUTVyPUCuOlMh\|ryP	NYe1[\|ZYOjJ2M{W2Olk>
UACC257	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7QOk4zKM7:TR?=	MojyO\|IhcA>?	NIP6fYNFVVOR	M4PlS2dKPTB;MD61JO69VQ>?	M4LKUlIzPDN3Nk[5
UACC62	NF7qTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXq2MlIh\|ryP	NI\iRXI4OiCq	NIfFXW1FVVOR	M17rVmdKPTB;MD60JO69VQ>?	NFXUfZAzOjR\|NU[2PS=>
UO31	MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDnOk4zKM7:TR?=	MlW3O\|IhcA>?	NGfUPZdFVVOR	M4fQTGdKPTB;MD61JO69VQ>?	Ml3XNlI1OzV4Nkm=
Hep3B	MnzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MW[0PEBp	MV3EUXNQ	M2TCWmdKPTB;MD62PUDPxE1?	MUSyNlQ{QTh4Mx?=
BE(2)-C	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NYDHNYpOPzJiaB?=	NXLuZ21bTE2VTx?=	MlfmTWM4OD1{IN88US=>	NH3JXlYzOjl\|MkOxOi=>
Bel7402	MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHLkdG04OiCq	NE\2UmlFVVOR	MVnHTVkxRTF5IN88US=>	NXHVPVhKOjNyNkGzO\|Y>
Bel7404	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWmzNo9PPzJiaB?=	MmTTSG1UVw>?	MV;HTVkxRTF6IN88US=>	NFntbpkzOzB4MUO3Oi=>
BGC823	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWe3NkBp	Mnr0SG1UVw>?	NFvUfI1IUTlyPUeuOUDPxE1?	M4LZUFI{ODZzM{e2
MGC803	NUP4TZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnvrO\|IhcA>?	NWfVZYpyTE2VTx?=	MY\HTVkxRTFyLkig{txO	NYHDeJdFOjNyNkGzO\|Y>
SGC7901	NFXVPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlfjO\|IhcA>?	MVvEUXNQ	NFPHW5ZIUTlyPUmuOEDPxE1?	Mle3NlMxPjF\|N{[=
SKHEP1	NVXnbowyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUjNTWNHPzJiaB?=	NH;6OHhFVVOR	NXHlbWNJT0l7ME2xO{DPxE1?	M1TjZlI{ODZzM{e2
SMMC7721	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUCze\|JmPzJiaB?=	Mn7mSG1UVw>?	MkK5S2k6OD1{MDFOwG0>	NInIS2czOzB4MUO3Oi=>
NUGC3	Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;KNVAh\|ryP			M4rGbGdKRTJwOUSg{txO	NUmzRWU4OjNzNkOzN\|I>
A2780 CisR	NHS3[ZBMcW6jc3WgRZN{[Xl?		M2fqcFE5KGh?		NWDRdXBVUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlQ1KM7:TR?=	M4fI[FI{OjV{NkCz
CAL27 sens	NHfHUYZMcW6jc3WgRZN{[Xl?		NYfROmg6OThiaB?=		MYfJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwM{[g{txO	MljrNlMzPTJ4MEO=
CAL27 CisR	M2XPOmtqdmG\|ZTDBd5NigQ>?		NX\MNVN5OThiaB?=		M1yyUWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NIjFUlUzOzJ3Mk[wNy=>
KYSE-510 CisR	MVPLbY5ie2ViQYPzZZk>		NYjEVm9lOThiaB?=		NIjqdmxKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOVkh\|ryP	NHrFOVIzOzJ3Mk[wNy=>
KYSE-510 sens	NYLLVJNxU2mwYYPlJGF{e2G7		Mly2NVghcA>?		MV3Jcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNzFOwG0>	M4rn[FI{OjV{NkCz
MDA-MB-231 sens	NYfxbphsU2mwYYPlJGF{e2G7		NIjXeWEyQCCq		NYfmc2VtUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	NGXCdY8zOzJ3Mk[wNy=>
MDA-MB-231 CisR	M2Dmc2tqdmG\|ZTDBd5NigQ>?		NWDLWWJjOThiaB?=		NYG3TWJlUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	M2\3RlI{OjV{NkCz
ES2	NILyVZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml:1OFghcA>?	MUjEUXNQ	NHfrU3ZKSzVyPUGyMlch\|ryP	NIO3[JQzOzR7M{S0PS=>
MDA-MB-231	MnjtT4lv[XOnIFHzd4F6	NH;oe2QyOCEQvF2=	MmK2N\|AhdWmw	NWTxVHR2TE2VTx?=	Ml;hTY5pcWKrdHnvckBw\iCKRFHDNoE>	MXyyN\|Q6OzR2OR?=
MDA-MB-231	MV\LbY5ie2ViQYPzZZk>	MWOxJO69VQ>?	NWn3e2U6OjRiaB?=	MXTEUXNQ	M37JSmlvcGmkaYTpc44hd2ZiSFTBR\|Yh[XO\|ZYPz[YQh[XNiYXPleJlt[XSrb36gcIV3\Wy\|IH;mJJR2[nWuaX6=	MV:yN\|Q6OzR2OR?=
HS68	NIDINWNEgXSxdH;4bYMhSXO\|YYm=	NEPiOWQyOCEQvF2=	NHjsdVU4OiCq	MkX1SG1UVw>?	MXHJR\|UxRTRwNjFOwG0>	MnXrNlM2PzB3NEK=
MEF	NIHmVm1EgXSxdH;4bYMhSXO\|YYm=	M1e0WFExKM7:TR?=	M3jNflczKGh?	NV\FXFdKTE2VTx?=	MkLNTWM2OD12LkSg{txO	MYiyN\|U4ODV2Mh?=
BGC823	NWHLW\|FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPEUXNQ	MWTHTVUxRTNwMEmg{txO	MX6yN\|YxOTdyNh?=
High5	MUTLbY5ie2ViQYPzZZk>		MYGyOEBp		NV7VfmFnUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDISGFEPiC5aYToJGlEPTBib3[gNE4xQSEQvF2=	NF;ndFQzOzZyMkWyNy=>
High5	Ml7BT4lv[XOnIFHzd4F6		NUjzOpl7OjRiaB?=		MXrJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOxJJdqfGhiSVO1NEBw\iByLkGyJO69VQ>?	MYSyN\|YxOjV{Mx?=
High5	MoHYT4lv[XOnIFHzd4F6		NHr2V\|YzPCCq		MX\Jcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KEiGQVOzJJdqfGhiSVO1NEBw\iByLkG3JO69VQ>?	MoC5NlM3ODJ3MkO=
A549	M3jycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWHQSFhiTE2VTx?=	MmXYTWM2OD1zLkC3PUDPxE1?	NHrYfnIzOzZ2NEKxNC=>
HCT116	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVXEUXNQ	NE\R[lBKSzVyPUCuO\|U4KM7:TR?=	MWiyN\|Y1PDJzMB?=
K562	NV7yS3R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVPNcXpITE2VTx?=	NXnDWnJPUUN3ME2wMlY1PSEQvF2=	Mle0NlM3PDR{MUC=
GBC-SD	MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDrOUDPxE1?	M4jhRlczKGh?	NXT1eJJrTE2VTx?=	MlfETWM2OD1zND64JO69VQ>?	MW[yN\|cxPzJ4MB?=
HGC27	MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVq1JO69VQ>?	NEXOW2Y4OiCq	NIP6N2RFVVOR	NFjSfY9KSzVyPUWuOEDPxE1?	MWWyN\|cxPzJ4MB?=
HL60	NUfpdnd3U2mwYYPlJGF{e2G7	MlXROUDPxE1?	NELQT\|AzPCCq	NUnKSoRSTE2VTx?=	MoLETY5pcWKrdHnvckBw\iCKRFHD	MXmyN\|cxPzJ4MB?=
Vero	NYH2dXNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1y0ZVczKGh?	MoLFSG1UVw>?	MXLJR\|UxRTBwOTFOwG0>	MmDzNlM4QDZ2NUK=
NCI60	MmDrR5l1d3SxeHnjJGF{e2G7		NVXjS\|BUPDhiaB?=	M4n0PWROW09?	NV[3O5dOT0l;MD61N{DPxE1?	NVHSVoxEOjRyMUWzNlc>
SW620	NUHYdpFTS3m2b4TvfIlkKEG\|c3H5		NIfPOXc1QCCq	NU\SeIY3TE2VTx?=	MmfpS2k:OC53NDFOwG0>	NIXhfW4zPDBzNUOyOy=>
U251	NHnveYZEgXSxdH;4bYMhSXO\|YYm=		MYO0PEBp	NW\CbFNkTE2VTx?=	M4jrZmdKRTFwNUOg{txO	NH\ic\|MzPDBzNUOyOy=>
KM12	MnvkR5l1d3SxeHnjJGF{e2G7		NGHGbIs1QCCq	NWfrU\|NJTE2VTx?=	NYD3epZET0l;MT64PEDPxE1?	NF3Mb20zPDBzNUOyOy=>
Hs578T	NYn3e\|BqS3m2b4TvfIlkKEG\|c3H5		NGH3ZnY1QCCq	Ml;KSG1UVw>?	M{D0VmdKRTRwOEOg{txO	MnTVNlQxOTV\|Mke=
MDA-MB-231	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGfENXE1QCCq		MYTJR\|UxRTBwMU[g{txO	NF\lUJIzPDB7NUCxOi=>
MCF7	NUDIbWpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NHjK[nQ1QCCq		MYXHTV0xNjR3IN88US=>	MnnvNlQyOTl3NUW=
MDA-MB-435	NFnDTGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1jqelQ5KGh?		MVTHTV0xNjh6IN88US=>	M173XlI1OTF7NUW1
AsPC1	M{n0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fN[VMxKM7:TR?=	MV:0PEBp	M1r2Z2ROW09?	MljNTWM2OD1\|Lk[2JO69VQ>?	NXLjTlVYOjRzOEWzO\|g>
Jurkat E6.1	MkjXT4lv[XOnIFHzd4F6		NEXPTpUzKGh?	MX;EUXNQ	M4W4SWlvcGmkaYTpc44hd2ZiSFTBR\|Qhf2m2aDDJR\|UxKG:oIECuNFQh\|ryP	NHnMVm0zPDJ4MUi2Ni=>
KG1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGSzcJY1QCCq		NHHYd4pKSzVyPUGuNVUh\|ryP	M2HCeFI1PTJ3MECz
HEL	NHOyOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NH21U4g1QCCq	NYT2fGN5TE2VTx?=	M{nDXWlEPTB;MD60PUDPxE1?	MXGyOFY6PDB3NR?=
HSC3	NVTDT3E4S3m2b4TvfIlkKEG\|c3H5		NVrLWVA3OTJiaB?=	NELJNVdFVVOR	NETocFVKSzVyPUCuO\|Eh\|ryP	Mn;uNlQ4PjZ3NkC=
HT-29	NFLqdIZEgXSxdH;4bYMhSXO\|YYm=		M3O1XVEzKGh?	M3jGemROW09?	M3TNTWlEPTB;MD63NkDPxE1?	MXSyOFc3PjV4MB?=
KB	MmLuR5l1d3SxeHnjJGF{e2G7		NHLGbVQyOiCq	M1rQdWROW09?	M4LTNmlEPTB;MD63OUDPxE1?	MofkNlQ4PjZ3NkC=
H460	MkPJR5l1d3SxeHnjJGF{e2G7		MojzNVIhcA>?	MmnTSG1UVw>?	NYjobGxQUUN3ME2wMlgzKM7:TR?=	M{D2[FI1PzZ4NU[w
MONE1	MV7DfZRwfG:6aXOgRZN{[Xl?		NEHi[m0yOiCq	MVTEUXNQ	M4[3bWlEPTB;MT6xPEDPxE1?	MUGyOFc3PjV4MB?=
MKN45	MkP5R5l1d3SxeHnjJGF{e2G7		NVXmUWR[OTJiaB?=	MV\EUXNQ	M3zOW2lEPTB;MT6yOUDPxE1?	NXSw[4lwOjR5Nk[1OlA>
TSGH	MmXBR5l1d3SxeHnjJGF{e2G7		M1flO\|EzKGh?	NV:4PYRPTE2VTx?=	M1rJ[2lEPTB;Mj6wPUDPxE1?	M{jWeFI1PzZ4NU[w
HL60	M2rzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NXfrXIF1PzJiaB?=	NILZeY1FVVOR	Ml22S2k2OD1yLkmzJO69VQ>?	NHnX[48zPDlyMEWwNC=>
HEK293	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3\HSFczKGh?	NVn2OGsxTE2VTx?=	M1nUUGdKPTB;MUOg{txO	NXXKPWgxOjR7MEC1NFA>
Jurkat	M{\LO2N6fG:2b4jpZ{BCe3OjeR?=	NFvDV48yODBizszN	MUW3NkBp		MVPHTVUxRTBwOTFOwG0>	NIHMOW0zPDlyMEe0Ny=>
GM15850	M1LvVWtqdmG\|ZTDBd5NigQ>?	M2G1[VIvPSEQvF2=	NXH1SVhuQTZiaB?=	Ml3VSG1UVw>?	Mmn0[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFE1KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NIG2[ogyPjl{MUO2Oy=>
GM15850	M1vJfGtqdmG\|ZTDBd5NigQ>?	NVvKVHB5Oi53IN88US=>	MV65OkBp	MlPuSG1UVw>?	M1XhbYRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA2KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NXTJU2VCOTZ7MkGzOlc>
GM15850	M4nCVmtqdmG\|ZTDBd5NigQ>?	NFz1bWQzNjVizszN	NWS3Zpo{QTZiaB?=	NWrZNnp5TE2VTx?=	M37V[IRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UAyOiCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NGP4ZYoyPjl{MUO2Oy=>
GM15850	NGPGRmVMcW6jc3WgRZN{[Xl?	MlXFNk42KM7:TR?=	NFHTOJE6PiCq	MmCySG1UVw>?	M1:zeIRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UA6KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	MWixOlkzOTN4Nx?=
GM15850	M{XLVGtqdmG\|ZTDBd5NigQ>?	MUiyMlUh\|ryP	MV65OkBp	NIrI[YVFVVOR	M1jIWoRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg1KGy7c3nu[UA5KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M2rsc\|E3QTJzM{[3
GM15850	M1rLNGtqdmG\|ZTDBd5NigQ>?	M3\iW\|IvPSEQvF2=	NUnZfo13QTZiaB?=	NXu4TJZzTE2VTx?=	NGHQfW5ld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTZiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	M17zRlE3QTJzM{[3
GM15850	NYrqcmlsTnWwY4Tpc44hSXO\|YYm=	MVy1JO69VQ>?	Mon4NVIhcA>?	MYPEUXNQ	M2HpfYhieyCwbzDl[oZm[3Rib36gSnhPKG2UTlGg[ZhxemW\|c3nvci=>	Mn;MNVY6OjF\|Nke=
U937	MkG1T4lv[XOnIFHzd4F6	MUG1JO69VQ>?	MUiyOEBp	MUfEUXNQ	NF;zZ\|Bp[XNibn:g[YZn\WO2IH;uJIFteGijIIT1ZpVtcW5iYXPleJlt[XSrb36=	MYixO\|Q1Pzd3MB?=
U937	M4jVRWtqdmG\|ZTDBd5NigQ>?	MmDVNUDPxE1?	MYmyOEBp	NXLHRW8yTE2VTx?=	Ml7ObIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	NWLHdlRqOTd2NEe3OVA>
PANC1	M{fQUmZ2dmO2aX;uJGF{e2G7	NE\pSpQyKM7:TR?=	NFPDbVIzPCCq		MY\kc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	NYLp[ohGOTd3OEi3OFQ>
PANC1	MnnISpVv[3Srb36gRZN{[Xl?	M1rQb\|Eh\|ryP	NWq5WXFGPDhiIHi=		MkDs[I9meyCwb4SgbY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	NX\OcoNCOTd3OEi3OFQ>
Caco-2	M3rtNWZ2dmO2aX;uJGF{e2G7	NV;ZT5VQPSEQvF2=	M2\teVI1KGh?	NV7NXHdXTE2VTx?=	NIG0PIJld2W\|IH7veEBqdmS3Y3WgVFIyX0GIMTDn[Y5mKGW6cILld5Nqd25?	MVWyNFE1Ozh2MB?=
SCC4	NIDTWIpHfW6ldHnvckBCe3OjeR?=	MVuxJO69VQ>?	NHXiRmQyOCCvaX6=	MXHEUXNQ	MV7oZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	M4fOblIxPDV{MkK1
A549	NEPROVVHfW6ldHnvckBCe3OjeR?=	MVK1JO69VQ>?	NE\MVI4{KGh?	M1rsTWROW09?	NXPKUpc1\G:nczDuc5QhcW6mdXPlJIF2fG:yaHHnfUBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR\|NKUQ>?	MlziNlA5PTV{MEi=
HCT116	Ml63T4lv[XOnIFHzd4F6	NGWyTJoxNjNizszN	NW\wfos1OzBiaB?=	MVvEUXNQ	NG[2dYJld2W\|IH7veEBqdmirYnn0JGhFSUNzIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqaYP0c45mKEh\|S{mgZYNmfHmuYYTpc44>	NYLxdZp4OjFyOEC2OFc>
HepG2	NXLEfWMxTnWwY4Tpc44hSXO\|YYm=	MmXRNVAh\|ryP	NG\Jc2QzPCCq	NXnmfnNyTE2VTx?=	MYHkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJIh6eGW{YXPleJlt[XSrb36gc4YheDV\|	NGLh[2QzOTV2OEW4Ni=>
GM11272	MYHGeY5kfGmxbjDBd5NigQ>?	MUOwMlEh\|ryP	NUj5R2tyPzJiaB?=	MVzEUXNQ	NXu5Um4{\G:nczDuc5QhemWjY4TpeoF1\SCPZVPwNkBufXSjboSg[ZhxemW\|c3nvci=>	MmW5NlE5PDB5MU[=
MDA-MB-231	NH34[ZZMcW6jc3WgRZN{[Xl?	MV[xNEDPxE1?	MWW1JI1qdg>?	NH71UFZFVVOR	M3XBWoRw\XNibn;0JIlvcGmkaYSgTGRCSzKj	MUiyN\|Q6OzR2OR?=
MDA-MB-231	NFXPPXpMcW6jc3WgRZN{[Xl?	NV3meYpPOSEQvF2=	NFfZSokzPCCq	Ml;JSG1UVw>?	MmfY[I9meyCwb4SgbY5pcWKrdDDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	NGjrW4MzOzR7M{S0PS=>
K562	NWGwfph3U2mwYYPlJGF{e2G7				M2Dhe4Rw\XNibn;0JIlvcGmkaYSgTGRCSw>?	MU[yN\|U6OTFzMR?=
Jurkat	M4nNN2N6fG:2b4jpZ{BCe3OjeR?=	NFjlSpYzOCEQvF2=	NHG2O5c4OiCq	MUTEUXNQ	NF\GWHZvdyCleYTveI95cWOrdImgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44>	NH3henczPDNyNEO0PC=>
HCT116	NHvpO2pCeG:ydH;zbZMhSXO\|YYm=	Mlj0N{DPxE1?	M4PHfFI1KGh?	NGHXXY5FVVOR	NXLWXZlX\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwOVMheHKxdHXpckBt\X[nbB?=	MkntNlQ4PjZ3NkC=
KASUMI-1	NF2yNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTl7LkG3JI5O	NF7leG5USU6JRWK=
KARPAS-45	NEXCWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rveGlEPTB;MUezMlg6KG6P	MYHTRW5ITVJ?
BHT-101	NF3GTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTXXYx4UUN3ME2yOFQvOThibl2=	NXTIUI1XW0GQR1XS
H9	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DjdWlEPTB;MkW1MlA1KG6P	NVPITWl6W0GQR1XS
PA-1	M4H2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXaTWM2OD1{OE[uNlYhdk1?	NUix[XFTW0GQR1XS
NEC8	NF\4[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfaTWM2OD1{OEmuN\|ghdk1?	MlHuV2FPT0WU
MHH-PREB-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:5TWM2OD1{OUSuOVMhdk1?	NGXMTYNUSU6JRWK=
NB7	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXJTWM2OD1\|NEWuO\|Qhdk1?	NIK4e5RUSU6JRWK=
A3-KAW	MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz2SJlmUUN3ME20NFAvPTlibl2=	M3LqVXNCVkeHUh?=
NB69	M1ryRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3NUnhKSzVyPUSxNU44OSCwTR?=	MV\TRW5ITVJ?
EoL-1-cell	NGewbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTR3NEK1JI5O	NWjuW5k3W0GQR1XS
CHP-212	MnHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX6ZWpPUUN3ME20OVcvPTNibl2=	NVPGZYhEW0GQR1XS
C2BBe1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jleWlEPTB;NEeyMlE6KG6P	NY\lTFFSW0GQR1XS
697	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGmzSnZKSzVyPUS3N{41OSCwTR?=	MnHkV2FPT0WU
BCPAP	NYTwV\|htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPHTWM2OD13MEGuOFIhdk1?	NWDkXpRFW0GQR1XS
L-363	M33Iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13ER2lEPTB;NUCzMlEhdk1?	M2rZbHNCVkeHUh?=
ES8	NHrXXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXVTWM2OD13MkOuOVMhdk1?	NYfPfYV1W0GQR1XS
BE-13	MlrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmmzTWM2OD13Mk[uPVYhdk1?	M2Tmb3NCVkeHUh?=
CTB-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfXTWM2OD13M{euPVIhdk1?	NFO4c\|ZUSU6JRWK=
HD-MY-Z	NHnKdlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTV\|OD6xN{BvVQ>?	NXfE[5g3W0GQR1XS
NKM-1	M4O0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\xU\|BKSzVyPUW0OE4zPyCwTR?=	NGm1TlFUSU6JRWK=
NCI-H720	M2HSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXKcXlKSzVyPUW2NE4yQCCwTR?=	MVnTRW5ITVJ?
KY821	NFHtcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPBTWM2OD13NkOuNlUhdk1?	MlX3V2FPT0WU
OVCAR-5	NEXpc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\jTWM2OD13N{[uNVEhdk1?	MUjTRW5ITVJ?
CTV-1	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\KUYFKSzVyPUW4NU42PiCwTR?=	M3PJcHNCVkeHUh?=
P12-ICHIKAWA	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\RPWlEPTB;NUm2MlUyKG6P	M4jXdHNCVkeHUh?=
DB	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjRW3FKSzVyPUW5PE42PyCwTR?=	NWTPeJk5W0GQR1XS
CHL-1	NIjtTVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjKSHFKSzVyPU[0Nk4xQCCwTR?=	NYX5U2ZlW0GQR1XS
A4-Fuk	NX7oOHVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjDfJRKSzVyPU[0OE46OSCwTR?=	NGe5SXdUSU6JRWK=
MV-4-11	NUfycI5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvRTWM2OD14NUmuNUBvVQ>?	NVnvPWQ2W0GQR1XS
RPMI-8226	NFHzbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzPU5Y{UUN3ME22O\|gvOThibl2=	M3zoU3NCVkeHUh?=
NB14	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7pTWM2OD14OU[uPVUhdk1?	Mnn2V2FPT0WU
DOHH-2	M3y0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUD0OGRMUUN3ME23NFYvPjhibl2=	M4S5fnNCVkeHUh?=
D-423MG	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTYTWM2OD15ME[uPFkhdk1?	NGDQfVhUSU6JRWK=
D-283MED	M1\6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTIRmRKSzVyPUexOE4yPCCwTR?=	M3nVW3NCVkeHUh?=
ES1	M3LqSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHnN5R3UUN3ME23NlQvPCCwTR?=	M4jrNHNCVkeHUh?=
GOTO	NFq2eY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTESXZKSzVyPUeyPU4yOiCwTR?=	MXrTRW5ITVJ?
NCI-H209	M33HfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;UTWM2OD15MkmuPUBvVQ>?	Mlz3V2FPT0WU
MOLT-13	M{LmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorETWM2OD15M{iuPVghdk1?	NXLYe25{W0GQR1XS
ATN-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTd2MD6yPEBvVQ>?	MX3TRW5ITVJ?
DU-4475	M4Dad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\G[WdoUUN3ME23OVEvQTFibl2=	NXHNWnYxW0GQR1XS
NB10	NIHmW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIm0d\|lKSzVyPUe1NU46OiCwTR?=	NI\XVGNUSU6JRWK=
KG-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\2TpdJUUN3ME23O\|UvPDVibl2=	NHqxdoZUSU6JRWK=
MOLT-4	NFjh[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTd6Nz60OkBvVQ>?	MX;TRW5ITVJ?
TE-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTd7MT6xJI5O	NUKyfVI1W0GQR1XS
SBC-1	NUDXOJViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLKTWM2OD15OUOuPFQhdk1?	NF3sOWRUSU6JRWK=
HEL	NILTTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Dye2lEPTB;OEC2MlA5KG6P	M3nTenNCVkeHUh?=
SK-MEL-2	M2PVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRThyOT60OEBvVQ>?	MXHTRW5ITVJ?
KU812	NX\q[\|c2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnz6TWM2OD16MUOuNUBvVQ>?	NGS4Nm1USU6JRWK=
RPMI-8866	M2rMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml\4TWM2OD16MUOuOlchdk1?	NGLMWYFUSU6JRWK=
ALL-PO	M{XGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfHO4tKSzVyPUixOE43PiCwTR?=	NGH5[mFUSU6JRWK=
LU-139	NY[0c3lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;4b\|E2UUN3ME24NlIvQDZibl2=	MlLkV2FPT0WU
RS4-11	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXOVZRKSzVyPUizNk41PSCwTR?=	MYrTRW5ITVJ?
EW-18	MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1[5bGlEPTB;OEOyMlk3KG6P	MnvRV2FPT0WU
P30-OHK	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDxR2FKSzVyPUizOU44KG6P	MYPTRW5ITVJ?
D-566MG	NGW3bJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnLdlhQUUN3ME24N\|gvPjJibl2=	MnrOV2FPT0WU
HSC-4	NX2xOYx5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTtZZFKSzVyPUi0Ok42OSCwTR?=	NYPQfphoW0GQR1XS
QIMR-WIL	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\ucmlEPTB;OE[yMlA{KG6P	MWTTRW5ITVJ?
SW954	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf0WI9bUUN3ME24OlMvOTZibl2=	NWG0O4hGW0GQR1XS
HGC-27	NX\kTmNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTlZVRtUUN3ME24O\|IvOzRibl2=	MXfTRW5ITVJ?
HH	M3jLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIr1R\|VKSzVyPUi5OE4yOiCwTR?=	MUPTRW5ITVJ?
KE-37	NFnSd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\jTG1KSzVyPUi5OE43OiCwTR?=	MUHTRW5ITVJ?
SK-N-DZ	M1PvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPBTWM2OD17MECuOFMhdk1?	M{TpRXNCVkeHUh?=
J-RT3-T3-5	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmG0TWM2OD17MUCuOFkhdk1?	NWr5O5h3W0GQR1XS
A427	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TZe2lEPTB;OUKwMlg1KG6P	MXLTRW5ITVJ?
ECC10	NFHXeWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{[ybGlEPTB;OUS1Mlg4KG6P	NF3Kdo9USU6JRWK=
EW-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3GTWM2OD17NEeuNlYhdk1?	MlzyV2FPT0WU
MIA-PaCa-2	NY\0[FZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXicZR4UUN3ME25OFkvOTJibl2=	Mn61V2FPT0WU
HCC2218	M1PCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{[4OmlEPTB;OUW4MlQ5KG6P	NHLXVphUSU6JRWK=
HAL-01	M1XjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\WN4ZXUUN3ME25OlgvODRibl2=	M3vzc3NCVkeHUh?=
RD	MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnm[2FKSzVyPUm3OE41PSCwTR?=	M4PYbXNCVkeHUh?=
SK-N-AS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjmZVdKSzVyPUm4PE4yKG6P	MV;TRW5ITVJ?
ML-2	M3;6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTBTWM2OD1zLkCwOFA4KM7:TR?=	Mke3V2FPT0WU
MEL-HO	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2PFcGlEPTB;MT6wNFU5OiEQvF2=	NHzJdWVUSU6JRWK=
MS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7jTWM2OD1zLkCwOlE4KM7:TR?=	NXLwb2V2W0GQR1XS
NCI-SNU-1	M1;3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4O1UmlEPTB;MT6wNlM{OSEQvF2=	NVPCNZFFW0GQR1XS
8505C	M3K5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTpTmgyUUN3ME2xMlAzOzNzIN88US=>	M{\vUnNCVkeHUh?=
MN-60	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTFwMEK2PEDPxE1?	MX7TRW5ITVJ?
SAS	MonlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrLTFBKSzVyPUGuNFQxQDFizszN	M{LEZXNCVkeHUh?=
EFM-19	NITEWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D1ZmlEPTB;MT6wOFg4QSEQvF2=	MlzNV2FPT0WU
Ca9-22	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\Cd2lEPTB;MT6wOVExPyEQvF2=	NF;IXJpUSU6JRWK=
NBsusSR	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnYdpRrUUN3ME2xMlA2OTZ4IN88US=>	NH3xcI5USU6JRWK=
NB13	NWjORmoyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTFwMEW1NFEh\|ryP	Mn\UV2FPT0WU
SF295	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrsWnQ3UUN3ME2xMlA3PjJ2IN88US=>	M17DZXNCVkeHUh?=
U-2-OS	M{\OeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLQTWM2OD1zLkC3PVEyKM7:TR?=	NYjGU3lLW0GQR1XS
NCI-H526	NXfZb5ZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnFdHRKSzVyPUGuNFgzQTFizszN	MVHTRW5ITVJ?
KMOE-2	NGjtWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnPTWM2OD1zLkC5OFIzKM7:TR?=	NGLjR2tUSU6JRWK=
RCM-1	MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlHhTWM2OD1zLkGyNVAzKM7:TR?=	MkL1V2FPT0WU
MC116	M4DjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;HVlhKSzVyPUGuNVM3OjFizszN	MVPTRW5ITVJ?
NCI-H1092	M3HpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTFwMUW0NFYh\|ryP	MWHTRW5ITVJ?
EW-3	M3\qWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:1VWlEPTB;MT6xO\|IyOiEQvF2=	MmHNV2FPT0WU
HCT-116	NWizNWRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwMUe3OUDPxE1?	MmrIV2FPT0WU
MC-IXC	NUXxNHNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rQfmlEPTB;MT6xO\|g5OSEQvF2=	NEPKfZBUSU6JRWK=
LB1047-RCC	M4iwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmTpTWM2OD1zLkG4N\|EzKM7:TR?=	MoO4V2FPT0WU
VM-CUB-1	NHTGWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPLd4tKSzVyPUGuNVkyODhizszN	NX3C[WV6W0GQR1XS
NB5	NYTjSmZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{T5UWlEPTB;MT6xPVg2PiEQvF2=	MmHrV2FPT0WU
SKG-IIIa	NH3FSFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDBTWM2OD1zLkKzOFY1KM7:TR?=	MYjTRW5ITVJ?
HO-1-N-1	NEXVR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTFwMkO4N\|Uh\|ryP	MX3TRW5ITVJ?
EFO-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHZfVNZUUN3ME2xMlI2ODR\|IN88US=>	M1\wWnNCVkeHUh?=
MHH-NB-11	NHTPcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HFT2lEPTB;MT6yPFMzQSEQvF2=	NXH1b3pIW0GQR1XS
SW620	NXi1blVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PlV2lEPTB;MT6yPVAyQCEQvF2=	MnHHV2FPT0WU
MOLT-16	M{TGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrGUVV[UUN3ME2xMlI6Pzl5IN88US=>	M2S4d3NCVkeHUh?=
NTERA-S-cl-D1	NWHENJliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXpTWM2OD1zLkOxO\|YyKM7:TR?=	M{mxOXNCVkeHUh?=
VA-ES-BJ	M{\nN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjFTWM2OD1zLkOyOFc4KM7:TR?=	NX;GR2tvW0GQR1XS
HCC1419	M3P3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvYTWM2OD1zLkO0NFI4KM7:TR?=	MVjTRW5ITVJ?
NCI-H69	M3HzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHmycW9KSzVyPUGuN\|QyOTJizszN	M2GwPXNCVkeHUh?=
DEL	NXjBR3NST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjMV3dKSzVyPUGuN\|UyPjJizszN	M4[yR3NCVkeHUh?=
LXF-289	NHnCUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwM{WyOEDPxE1?	NHr5XIpUSU6JRWK=
EW-11	MlHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;CNXhnUUN3ME2xMlM3ODJ4IN88US=>	MX7TRW5ITVJ?
KP-4	NUDDepJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XXTGlEPTB;MT6zO\|A5PSEQvF2=	M4TP[HNCVkeHUh?=
NOS-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTFwNEGxPVQh\|ryP	NFPXZZVUSU6JRWK=
SK-NEP-1	NHzCc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7XXY9KSzVyPUGuOFE3QTNizszN	MYPTRW5ITVJ?
LAMA-84	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jZUmlEPTB;MT60N\|k1PSEQvF2=	MWrTRW5ITVJ?
ES5	M4nnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zHOmlEPTB;MT60OFMh\|ryP	MljyV2FPT0WU
HuO9	MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\Q[G81UUN3ME2xMlQ2OzZ{IN88US=>	NVK5epFNW0GQR1XS
COLO-684	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVT3[5d7UUN3ME2xMlQ3OTF6IN88US=>	NUDPT41FW0GQR1XS
EW-24	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4LJWWlEPTB;MT60OlU{OSEQvF2=	M{j3SnNCVkeHUh?=
BV-173	M4[5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwNEeyPVEh\|ryP	NYXyUIptW0GQR1XS
NCI-H1770	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTFwNEi1N\|Yh\|ryP	NXHTSpE4W0GQR1XS
HuP-T4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7mTWM2OD1zLkS5N{DPxE1?	NHL1bWRUSU6JRWK=
TYK-nu	NEC1eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrTU4tKUUN3ME2xMlQ6QDVzIN88US=>	M4WyUHNCVkeHUh?=
YH-13	NF7JO\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1flVmlEPTB;MT60PVg6PCEQvF2=	M3HRbHNCVkeHUh?=
H4	M1eydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX5VJNXUUN3ME2xMlUxQTF{IN88US=>	MlnZV2FPT0WU
OVCAR-8	NFz2UJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFwNUS0O\|ch\|ryP	NECwR5JUSU6JRWK=
NCI-H23	NVXGd2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFL1SI9KSzVyPUGuOVQ3PDVizszN	MVvTRW5ITVJ?
ES7	NFT4c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLaVnhrUUN3ME2xMlU1Pzd\|IN88US=>	NXfvZnZtW0GQR1XS
COR-L88	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nDUWlEPTB;MT61OlQzPCEQvF2=	NFrKNo9USU6JRWK=
TI-73	NIj0OYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwNUmwOkDPxE1?	MXrTRW5ITVJ?
RT-112	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfRTWM2OD1zLkW5Nlg1KM7:TR?=	NGW4WmNUSU6JRWK=
HuO-3N1	M2fRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\5VmlEPTB;MT61PVM5PSEQvF2=	M3XzdnNCVkeHUh?=
HC-1	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTFwNUm4OlYh\|ryP	M4C0VXNCVkeHUh?=
HT55	MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjVN\|hXUUN3ME2xMlY2OTNzIN88US=>	NGLXUHdUSU6JRWK=
IA-LM	NWDBc2dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XvVGlEPTB;MT62PVI4QCEQvF2=	NX;oVXJFW0GQR1XS
EM-2	NVvyPHdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFwN{CwNVQh\|ryP	Mk\PV2FPT0WU
MHH-ES-1	NX20cnZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrCWok3UUN3ME2xMlcxPDN3IN88US=>	MkS0V2FPT0WU
CAL-27	NHjBZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFG1WIxKSzVyPUGuO\|A3OjFizszN	MUnTRW5ITVJ?
COLO-800	NYfxTZNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmS0TWM2OD1zLkexNVc6KM7:TR?=	MULTRW5ITVJ?
HCE-T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTFwN{G1JO69VQ>?	MlrqV2FPT0WU
CAMA-1	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fiWWlEPTB;MT63NVk4OSEQvF2=	NHPQNYtUSU6JRWK=
LOXIMVI	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nKNWlEPTB;MT63NlEyKM7:TR?=	NFTaTZlUSU6JRWK=
NH-12	NFjiO\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFj6UmZKSzVyPUGuO\|I3QTFizszN	MlTXV2FPT0WU
TCCSUP	NF\2RXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T6WmlEPTB;MT63NlgzQSEQvF2=	NUHhZZhOW0GQR1XS
MDA-MB-361	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorTTWM2OD1zLkezNVU4KM7:TR?=	NWLDcGxEW0GQR1XS
EW-16	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2GyU2lEPTB;MT63OFExPyEQvF2=	Mk\6V2FPT0WU
SNU-423	MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTFwN{W4Nlch\|ryP	M3TtfHNCVkeHUh?=
Daoy	NG[zZ3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFwN{[zNVkh\|ryP	MVfTRW5ITVJ?
ES4	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzTW\|B2UUN3ME2xMlc5PzRzIN88US=>	M1\xUHNCVkeHUh?=
PFSK-1	M{jwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;kVY1KSzVyPUGuPFA{PyEQvF2=	M3;DfXNCVkeHUh?=
ES3	NWP3[mNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnu1TWM2OD1zLkiyOlgyKM7:TR?=	NGf3e4RUSU6JRWK=
ONS-76	Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{P2XWlEPTB;MT64Nlg6PyEQvF2=	NVnBWVdYW0GQR1XS
JVM-3	NYLFfnNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoHrTWM2OD1zLki1OFUyKM7:TR?=	M3jFXXNCVkeHUh?=
OS-RC-2	NYnDWZFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTFwOEexOVEh\|ryP	MoXSV2FPT0WU
COLO-320-HSR	M{i0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P1VmlEPTB;MT64PFE6PyEQvF2=	NUDyOIF6W0GQR1XS
HN	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTFwOEi3NlUh\|ryP	M{jwWXNCVkeHUh?=
HT	NXqwSIt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPnTWM2OD1zLki4PVQ4KM7:TR?=	NUHtboxHW0GQR1XS
LoVo	M2nPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTFwOEm4NUDPxE1?	MXjTRW5ITVJ?
CGTH-W-1	NY\F[VFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUC1U49uUUN3ME2xMlg6QTR4IN88US=>	M{jqUnNCVkeHUh?=
NB6	M1jORmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTFwOUGyPVgh\|ryP	MXPTRW5ITVJ?
EW-22	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTFwOUK4PFch\|ryP	NXvIPXNVW0GQR1XS
ES6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGKycYFKSzVyPUGuPVM3OzFizszN	NVyyboRjW0GQR1XS
SCC-15	MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[3ZoNnUUN3ME2xMlk{QDF7IN88US=>	MkjQV2FPT0WU
HL-60	NEfORlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnj0TWM2OD1zLkmzPVAzKM7:TR?=	NYrxcXdKW0GQR1XS
human HOP-92	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvjTWM2OD1zLkm0NFY2KM7:TR?=	NH\HbWNUSU6JRWK=
SW626	NYDSUG5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XIfmlEPTB;MT65OFg6QSEQvF2=	M1fEdXNCVkeHUh?=
HEC-1	NHGxS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUm3VopyUUN3ME2xMlk2OzZizszN	NF7zXmlUSU6JRWK=
LB2241-RCC	MnfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUe2UmI3UUN3ME2xMlk5OjNzIN88US=>	NFTNcIdUSU6JRWK=
Ramos-2G6-4C10	M3rYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnNbZdoUUN3ME2xMlk6PDl\|IN88US=>	NUXLRpdNW0GQR1XS
A101D	NHfyOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJwMkCzNFMh\|ryP	NHTZe5ZUSU6JRWK=
NCI-H446	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYWzVpV7UUN3ME2yMlA1PTl7IN88US=>	NVzCb2o3W0GQR1XS
SBC-5	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTJwME[xOFch\|ryP	M1fuV3NCVkeHUh?=
HOS	NH7rN5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVG4R2dmUUN3ME2yMlA4PjV\|IN88US=>	M2rRcXNCVkeHUh?=
K5	M3;QUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUjMPWF5UUN3ME2yMlA4QDFzIN88US=>	M1z6VnNCVkeHUh?=
HLE	NF7YdHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4D6cmlEPTB;Mj6wPFUzQSEQvF2=	MV\TRW5ITVJ?
HSC-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuwTWM2OD1{LkGyPFk5KM7:TR?=	MljiV2FPT0WU
LCLC-97TM1	M3XGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTJwMUS1PFMh\|ryP	MX;TRW5ITVJ?
DMS-273	M{XaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTJwMUS4N\|ch\|ryP	MmLqV2FPT0WU
TE-8	NUXaTZZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3LZoJKSzVyPUKuNVU4PjVizszN	Mn\CV2FPT0WU
DSH1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny2TWM2OD1{LkG2N\|k5KM7:TR?=	NUT0WmdOW0GQR1XS
CAL-51	NF\EdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILmTXdKSzVyPUKuNVY3QTlizszN	MXTTRW5ITVJ?
IST-SL1	M3;G[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTJwMU[4OFQh\|ryP	M{D1eHNCVkeHUh?=
GCT	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7hZ29KSzVyPUKuNVc4PyEQvF2=	NHX4SFFUSU6JRWK=
SW948	NWjXTHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjxb3dKSzVyPUKuNVg1PTZizszN	MmXqV2FPT0WU
NOMO-1	M37CfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJwMUmzNVch\|ryP	M1TBR3NCVkeHUh?=
C8166	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTXW3ZuUUN3ME2yMlIyOzN2IN88US=>	NGLPNWxUSU6JRWK=
OC-314	NIHzNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJwMkOyOVkh\|ryP	NUPFWJY2W0GQR1XS
CAL-39	M2\NXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzTTWM2OD1{LkKzOlI3KM7:TR?=	M4PrcnNCVkeHUh?=
MDA-MB-453	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInte3dKSzVyPUKuNlQzPzVizszN	MXPTRW5ITVJ?
A673	M4WwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjoU4VKSzVyPUKuNlU5PjJizszN	MVnTRW5ITVJ?
HTC-C3	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7nTWM2OD1{LkK2PFUh\|ryP	MlnXV2FPT0WU
NCI-H1666	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DXVmlEPTB;Mj6yPFEyOSEQvF2=	MWjTRW5ITVJ?
PSN1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M32xV2lEPTB;Mj6yPFkyOyEQvF2=	M4HY[nNCVkeHUh?=
GI-1	NYrBdm5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJwM{C1OFMh\|ryP	MkCzV2FPT0WU
HuH-7	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjKdWtKSzVyPUKuN\|A3OzdizszN	NV35Nok{W0GQR1XS
JAR	NWXocHhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfWUYxZUUN3ME2yMlMyQTh5IN88US=>	M1GxPHNCVkeHUh?=
5637	NUHVbFViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTJwM{KxNlkh\|ryP	MVTTRW5ITVJ?
GB-1	NFXwXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrZOW5iUUN3ME2yMlMzOzN3IN88US=>	NYG2dIZLW0GQR1XS
KP-N-YS	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HQ[mlEPTB;Mj6zNlYyPSEQvF2=	NV3ve2JQW0GQR1XS
OAW-42	NX\0[ZJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jVTWlEPTB;Mj6zN\|QyPiEQvF2=	MWPTRW5ITVJ?
8-MG-BA	Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\CSWJQUUN3ME2yMlM{QTB4IN88US=>	MkPaV2FPT0WU
RH-18	M{jQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXacJJKSzVyPUKuN\|UxOjJizszN	MYjTRW5ITVJ?
NCI-H1155	NV33ZpV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLRb2wzUUN3ME2yMlM3PzJ3IN88US=>	MVrTRW5ITVJ?
NB17	NUHyXVE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPwNXlrUUN3ME2yMlM5OjR\|IN88US=>	NU[2UGZsW0GQR1XS
NCI-H1437	M3;admdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVjZdGRDUUN3ME2yMlQyQDd\|IN88US=>	NIXoNVZUSU6JRWK=
SN12C	NH3vdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnSTWM2OD1{LkSzNlE1KM7:TR?=	MW\TRW5ITVJ?
HSC-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwNES1NFkh\|ryP	MkTrV2FPT0WU
GAMG	NFjrW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn71TWM2OD1{LkS0OVYyKM7:TR?=	NFLjVHFUSU6JRWK=
HT-1080	NXS5THBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWD3PGd[UUN3ME2yMlQ1QDZ2IN88US=>	MWHTRW5ITVJ?
A549	NXXvb25yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{P2Z2lEPTB;Mj60OFg6OyEQvF2=	NYf2ZmIyW0GQR1XS
KNS-62	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;t[WZKSzVyPUKuOFUxPjFizszN	MXXTRW5ITVJ?
YKG-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rmR2lEPTB;Mj60OVQ{PyEQvF2=	MnPxV2FPT0WU
LU-134-A	NWjwTItqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf3TWM2OD1{LkS3NFA5KM7:TR?=	NH;BOFlUSU6JRWK=
FADU	M4nEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fPTWlEPTB;Mj60O\|E3OiEQvF2=	NGC2R5hUSU6JRWK=
TGBC11TKB	NH\FPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIKxTYdKSzVyPUKuOFcyPzdizszN	MlnwV2FPT0WU
HT-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJwNEm1N\|Uh\|ryP	MoTzV2FPT0WU
NCI-H2170	NYnNTJRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHJUWo1UUN3ME2yMlUxPTR7IN88US=>	NWXvWFlnW0GQR1XS
Mo-T	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1;VSmlEPTB;Mj61NFkzPyEQvF2=	MYLTRW5ITVJ?
CCRF-CEM	NX7YN2FVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJwNUOwOFMh\|ryP	NH\QcphUSU6JRWK=
KU-19-19	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm1WGRwUUN3ME2yMlU{PTF\|IN88US=>	NYjGV\|l6W0GQR1XS
NCI-H1048	NGXpe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fJdWlEPTB;Mj61OVAzPSEQvF2=	MV7TRW5ITVJ?
KOSC-2	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojQTWM2OD1{LkW2NFc3KM7:TR?=	MlPXV2FPT0WU
A431	NF2yNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfzTWM2OD1{LkW2N\|M2KM7:TR?=	MlLOV2FPT0WU
COR-L23	NHfKOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XDc2lEPTB;Mj61PFU3PiEQvF2=	NF[zOpFUSU6JRWK=
MKN28	M1fi[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTJwNUmwN\|ch\|ryP	NWfWS2VpW0GQR1XS
22RV1	NEDsXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJwNUmyO\|Qh\|ryP	MormV2FPT0WU
ABC-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3O1c2lEPTB;Mj62NFQ3KM7:TR?=	Mn;3V2FPT0WU
NCI-H2126	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTJwNkC5PFQh\|ryP	M{ToTXNCVkeHUh?=
DoTc2-4510	M4HkeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXkSXZKSzVyPUKuOlIyQDVizszN	MX\TRW5ITVJ?
SCC-4	NFXqeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDNTWM2OD1{Lk[zNFEzKM7:TR?=	NYrsNHlUW0GQR1XS
NCI-H661	NVfnNJpnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXm3eldzUUN3ME2yMlY1ODh3IN88US=>	MoTYV2FPT0WU
RPMI-2650	NWjuPGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWXJR\|UxRTJwNkSxOFMh\|ryP	Mn7GV2FPT0WU
NCI-H510A	M{fTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTJwNkS0NlYh\|ryP	MVLTRW5ITVJ?
BPH-1	M2HtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrrPIJKSzVyPUKuOlU5PSEQvF2=	M{Da[3NCVkeHUh?=
M14	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnFVJFKSzVyPUKuOlY6QTNizszN	NYTTUnRHW0GQR1XS
G-402	NF7ISFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI[yZXlKSzVyPUKuO\|A1PTFizszN	NIjEfGxUSU6JRWK=
AsPC-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3;wVGlEPTB;Mj63NVE4KM7:TR?=	NYq1e3czW0GQR1XS
NB12	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTJwN{G3NUDPxE1?	NHH1XnpUSU6JRWK=
SK-HEP-1	NYS5TFU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13udGlEPTB;Mj63OFM6OSEQvF2=	MmPkV2FPT0WU
U-266	M{HpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJwN{exNlEh\|ryP	M4nWc3NCVkeHUh?=
AM-38	M1rSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnztTWM2OD1{Lke3N\|U2KM7:TR?=	MX;TRW5ITVJ?
PC-14	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJwOEC1NUDPxE1?	M2LlUnNCVkeHUh?=
EGI-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvPTWM2OD1{LkixO\|Q{KM7:TR?=	MV\TRW5ITVJ?
LS-411N	NETx[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEjLb5NKSzVyPUKuPFI{OyEQvF2=	NV;wfItNW0GQR1XS
BFTC-905	M{PjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[wSmpYUUN3ME2yMlg2PTJ\|IN88US=>	MW\TRW5ITVJ?
CaR-1	NHzvRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjGfnpKSzVyPUKuPFYh\|ryP	NHvQZ5BUSU6JRWK=
NCI-H292	NUXlcYlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2L1Z2lEPTB;Mj64OlU6PiEQvF2=	NWDr[IY3W0GQR1XS
8305C	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJwOE[2OFUh\|ryP	M{DqXHNCVkeHUh?=
SNU-449	MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vPfmlEPTB;Mj64PVE5OiEQvF2=	NUPVTll6W0GQR1XS
LCLC-103H	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwOUC0N\|gh\|ryP	MUDTRW5ITVJ?
SW1573	Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\TTWM2OD1{Lkm2NFgzKM7:TR?=	MnrjV2FPT0WU
MLMA	NXq1WWRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTvTWM2OD1{Lkm2O\|E4KM7:TR?=	MUDTRW5ITVJ?
NCI-H1355	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHTv[4NKSzVyPUOuNFA4QTZizszN	MYnTRW5ITVJ?
RMG-I	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXSVXFKSzVyPUOuNFI2QTJizszN	MUPTRW5ITVJ?
BB65-RCC	MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVKyU\|ZQUUN3ME2zMlA{OzF2IN88US=>	M3vYe3NCVkeHUh?=
PC-3	Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7IfVlKSzVyPUOuNFM5PzRizszN	NHjsb2RUSU6JRWK=
SF268	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRTNwMES1NlMh\|ryP	NHrmW4pUSU6JRWK=
NCI-H810	M1T5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTNwMES4NlMh\|ryP	M2rnVnNCVkeHUh?=
MEG-01	M{fqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MofUTWM2OD1\|LkC2NVY1KM7:TR?=	M1v1N3NCVkeHUh?=
SW13	NIixR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrEeGVJUUN3ME2zMlA4QDR5IN88US=>	MY\TRW5ITVJ?
RH-1	NVjhc3pXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTNwMUCyO\|gh\|ryP	NUnvVItjW0GQR1XS
GT3TKB	NH[1cmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDUTWM2OD1\|LkGxNlg{KM7:TR?=	NHLn[VFUSU6JRWK=
TK10	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2nYOGlEPTB;Mz6xN\|czPCEQvF2=	NHLu[WtUSU6JRWK=
T-24	NV22NnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LPZmlEPTB;Mz6xOVA4KM7:TR?=	MYnTRW5ITVJ?
A498	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTNwMkC4O\|Eh\|ryP	NUjmUWRZW0GQR1XS
GR-ST	Mnn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\ZW5FXUUN3ME2zMlIzOTN7IN88US=>	NFjTSmFUSU6JRWK=
LB2518-MEL	M3PN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTNwMkKzPVgh\|ryP	MULTRW5ITVJ?
T47D	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGfFSHNKSzVyPUOuNlM3OjdizszN	NX;uTnRuW0GQR1XS
NCI-H1651	NIrSfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXIWY5WUUN3ME2zMlI1PjR2IN88US=>	NX\nZXBDW0GQR1XS
EC-GI-10	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEP0PINKSzVyPUOuNlYyPTNizszN	NWTOV3RFW0GQR1XS
HT-29	M3HOTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTNwMk[2NVQh\|ryP	MlLvV2FPT0WU
GI-ME-N	NXnGXI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrIeWc6UUN3ME2zMlI6PTFzIN88US=>	NECwWFhUSU6JRWK=
SW756	NVjY[FlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXITWM2OD1\|LkK5OlI6KM7:TR?=	NFHySZhUSU6JRWK=
RKO	NX\BVHJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfsZmNnUUN3ME2zMlMxPzV5IN88US=>	M3\qe3NCVkeHUh?=
NCI-H1563	NYDJWohQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH6wXGtKSzVyPUOuN\|MxOThizszN	M2fRS3NCVkeHUh?=
DJM-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DMN2lEPTB;Mz6zO\|Y4PCEQvF2=	M3PXSnNCVkeHUh?=
L-428	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrROmlKSzVyPUOuOFAxPDVizszN	NIPHXW1USU6JRWK=
NCI-H2122	NF;wc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r5NWlEPTB;Mz60NVMyOiEQvF2=	NITrXYJUSU6JRWK=
Ca-Ski	NUjLUIZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEno[plKSzVyPUOuOFU1OyEQvF2=	NVTQWXpMW0GQR1XS
639-V	M2Cz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDuR3pKSzVyPUOuOFYxPTdizszN	NVzmenQzW0GQR1XS
SW1116	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTNwNE[yOlkh\|ryP	M3n5RXNCVkeHUh?=
DMS-114	NX6wNHozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPkZ49pUUN3ME2zMlQ4ODZ4IN88US=>	M3zBZ3NCVkeHUh?=
MZ2-MEL	M1ezSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvYd5VFUUN3ME2zMlQ4PjhzIN88US=>	MWHTRW5ITVJ?
COLO-829	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;zTWM2OD1\|LkWwNFc{KM7:TR?=	NHTyXmhUSU6JRWK=
J82	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkfrTWM2OD1\|LkWwOVch\|ryP	NVjaWnhZW0GQR1XS
EW-13	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jxR2lEPTB;Mz61NlUyKM7:TR?=	MoXMV2FPT0WU
RXF393	M3vYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTNwNUOyPVQh\|ryP	MVXTRW5ITVJ?
CAL-62	M4LNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzQTI1KSzVyPUOuOVQ2OTRizszN	NUeyU4VHW0GQR1XS
OCUB-M	M3PIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnf2TWM2OD1\|LkW0OlY2KM7:TR?=	NHzEfpBUSU6JRWK=
BT-474	MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfwOWJKSzVyPUOuOlM{OSEQvF2=	MmToV2FPT0WU
KYSE-180	M4LMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7rboRKSzVyPUOuOlM{PzJizszN	MWjTRW5ITVJ?
NCI-H650	MoLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTNwNkSyPFch\|ryP	MmfVV2FPT0WU
Detroit562	NFi3XHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDGOHlKSzVyPUOuOlUxOjJizszN	MWTTRW5ITVJ?
SW48	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTNwNkW2OVch\|ryP	MX;TRW5ITVJ?
KYSE-450	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrmeVdKSzVyPUOuOlg2QDJizszN	MorrV2FPT0WU
KYSE-510	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPQTWM2OD1\|LkeyNVgyKM7:TR?=	MkXJV2FPT0WU
GP5d	M2PjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTNwN{K5OUDPxE1?	NWX0e4EzW0GQR1XS
RPMI-7951	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLtTWM2OD1\|Lke0O\|I{KM7:TR?=	M2HXWnNCVkeHUh?=
Becker	NV\DU\|lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PmOGlEPTB;Mz63OVAyOiEQvF2=	MnfQV2FPT0WU
WM-115	NXfQRmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmW2TWM2OD1\|Lke4NVk2KM7:TR?=	NFHsXVJUSU6JRWK=
G-401	M1XXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrUO\|JYUUN3ME2zMlc6ODh3IN88US=>	M2HvN3NCVkeHUh?=
PANC-08-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vRb2lEPTB;Mz63PVYxOiEQvF2=	NFrKXnBUSU6JRWK=
SW982	NFPxPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDUWlNKSzVyPUOuPFA2PTFizszN	MoDtV2FPT0WU
D-263MG	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDJU2pMUUN3ME2zMlgzODVzIN88US=>	MoXYV2FPT0WU
KM-H2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXz2e4ZJUUN3ME2zMlgzPjJ2IN88US=>	MYnTRW5ITVJ?
SK-MEL-3	M2\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTDTWM2OD1\|LkiyPFQyKM7:TR?=	NVPMWVljW0GQR1XS
NCI-H1581	NEO0PY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[zb3dKSzVyPUOuPFQ1QDhizszN	MnXNV2FPT0WU
LS-123	NEnYb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfsTWM2OD1\|Lki3PVA6KM7:TR?=	MnnKV2FPT0WU
CAKI-1	M2jOc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTNwOEmwOVIh\|ryP	MXjTRW5ITVJ?
MEL-JUSO	MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY[0boVnUUN3ME2zMlg6OTV\|IN88US=>	M3HrenNCVkeHUh?=
HCE-4	NI\LOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXCVnVsUUN3ME2zMlkyPjZ\|IN88US=>	Ml;IV2FPT0WU
TE-10	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4S0XGlEPTB;Mz65NlAyKM7:TR?=	NHnDdnJUSU6JRWK=
OVCAR-4	NGDEbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mln3TWM2OD1\|LkmyPFg6KM7:TR?=	MVHTRW5ITVJ?
ETK-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFuwfXZKSzVyPUOuPVQ3OzVizszN	Moj4V2FPT0WU
A2780	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTRwMEW5OlYh\|ryP	MojzV2FPT0WU
LU-65	MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{fiOWlEPTB;ND6wO\|Y{OyEQvF2=	NEXqSYdUSU6JRWK=
BHY	M3nnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIj6dpdKSzVyPUSuNVI1QTVizszN	MWPTRW5ITVJ?
COR-L105	M4LiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYK1SnRsUUN3ME20MlE{ODVzIN88US=>	NVPRNVlCW0GQR1XS
CAL-12T	M4\2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\s[5VKSzVyPUSuNVMyODNizszN	NWnaUoIzW0GQR1XS
SCH	M3rkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnQTWM2OD12LkG1O\|Q{KM7:TR?=	MUXTRW5ITVJ?
CW-2	M{nlfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfwTWM2OD12LkG5NFAyKM7:TR?=	MWXTRW5ITVJ?
HCC1806	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYq5bZVGUUN3ME20MlIxOzF{IN88US=>	MYfTRW5ITVJ?
KP-N-YN	M1HqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1e4SmlEPTB;ND6yNFkzPyEQvF2=	NVPoVm1DW0GQR1XS
T98G	MmrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7SUpZYUUN3ME20MlIzOTV5IN88US=>	M1Pje3NCVkeHUh?=
CAL-54	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrmTWM2OD12LkKyN\|gyKM7:TR?=	NIjG[3lUSU6JRWK=
CAL-33	NVHVSWJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\GUJZRUUN3ME20MlI{ODZ2IN88US=>	MlHVV2FPT0WU
SNU-C2B	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX:1WXliUUN3ME20MlI1PzZ7IN88US=>	NFW4R5hUSU6JRWK=
NUGC-3	Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfoTWM2OD12LkK1OVA2KM7:TR?=	MmjTV2FPT0WU
DOK	M{LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVj4RY82UUN3ME20MlI3PTl\|IN88US=>	M3HZSXNCVkeHUh?=
MMAC-SF	Mk\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTRwMk[4OVkh\|ryP	MnXBV2FPT0WU
KYSE-70	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33Ie2lEPTB;ND6yPVM1KM7:TR?=	M4i3S3NCVkeHUh?=
A204	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;1TWM2OD12LkO1PFA{KM7:TR?=	NEL0VnZUSU6JRWK=
SCC-25	M3;seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIH4cZZKSzVyPUSuN\|U5OTlizszN	MVTTRW5ITVJ?
EPLC-272H	NWP2PHQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PjWmlEPTB;ND6zPFk2KM7:TR?=	NVHoV5pbW0GQR1XS
CAL-120	NFmzdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTRwM{i5PVIh\|ryP	NH7rbGFUSU6JRWK=
LS-513	M2XqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LTS2lEPTB;ND60NlE6QCEQvF2=	MUPTRW5ITVJ?
CAPAN-1	MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTRwNEKzPFIh\|ryP	NVXBTGczW0GQR1XS
ESS-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTRwNEK3NlQh\|ryP	NHzRZnhUSU6JRWK=
GMS-10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;DZ\|JKSzVyPUSuOFI5OTlizszN	NIDP[otUSU6JRWK=
NCI-N87	M3fBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TCR2lEPTB;ND61NFg3QCEQvF2=	MVnTRW5ITVJ?
HMV-II	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTRwNUG3N{DPxE1?	Ml75V2FPT0WU
COLO-741	NVzKdmNVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq4TWM2OD12LkW1PVk1KM7:TR?=	NUnZd49kW0GQR1XS
MKN45	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXXTYpKSzVyPUSuOVc4OzJizszN	Mnn4V2FPT0WU
OAW-28	NH34dYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3qTWM2OD12LkW4N\|k5KM7:TR?=	M1vGVnNCVkeHUh?=
OCI-AML2	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYKxNnl7UUN3ME20MlY2OjN6IN88US=>	MVXTRW5ITVJ?
MDA-MB-231	Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmm2TWM2OD12LkewNlQ{KM7:TR?=	NH3DbZZUSU6JRWK=
NCI-H1648	M2f3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPZTJdOUUN3ME20MlczOjd\|IN88US=>	NF;4THVUSU6JRWK=
NCI-H1792	M4PibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnCTWM2OD12Lke2NVA4KM7:TR?=	M17Fb3NCVkeHUh?=
GCIY	Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHpdFZKSzVyPUSuO\|c1OjRizszN	NXfnNIJxW0GQR1XS
Hs-578-T	MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLxSYNKSzVyPUSuO\|c3PTVizszN	NWPTRZJGW0GQR1XS
SW962	Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTRwN{iwNVEh\|ryP	MlLpV2FPT0WU
NCI-H630	NFf3bnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLTTWM2OD12Lke4NFgyKM7:TR?=	NWf6V2dTW0GQR1XS
786-0	NIHTOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYD5UHBOUUN3ME20Mlc5Pzd\|IN88US=>	M2rxTHNCVkeHUh?=
FTC-133	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\u[HVCUUN3ME20Mlc6OjZ\|IN88US=>	Mn\6V2FPT0WU
BT-20	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTRwN{m0Nlkh\|ryP	Mn3uV2FPT0WU
Mewo	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYn2W41sUUN3ME20MlgyPzR5IN88US=>	NWXBd\|lnW0GQR1XS
SW780	NHO3UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXTTWM2OD12Lki1O\|Y3KM7:TR?=	NHXwcHlUSU6JRWK=
OE33	NFfJV45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTRwOEe3NVMh\|ryP	MkLBV2FPT0WU
HCC1569	M4fSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTRwOEi0OVgh\|ryP	NXrkT5BqW0GQR1XS
TE-6	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TWSmlEPTB;ND65N\|k4PyEQvF2=	NWXOTJVxW0GQR1XS
SK-N-FI	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LXOWlEPTB;ND65OFQzOSEQvF2=	MnjsV2FPT0WU
PANC-03-27	NHm1WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTRwOUm5OlIh\|ryP	MoHoV2FPT0WU
MCF7	M3fpcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX:1XYxLUUN3ME21MlAxPzN6IN88US=>	NV;RVHNZW0GQR1XS
UACC-257	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTVwMEK4OFUh\|ryP	NHfEeYlUSU6JRWK=
SW1088	NGTPZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf3[29CUUN3ME21MlAzQTR2IN88US=>	MYTTRW5ITVJ?
A704	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTVwMEOwOkDPxE1?	NF3SdVJUSU6JRWK=
A2058	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jUbmlEPTB;NT6wOVkxQCEQvF2=	MlnXV2FPT0WU
Calu-3	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vKPGlEPTB;NT6wOlQ2OiEQvF2=	NV3hTHhNW0GQR1XS
RERF-LC-MS	NGLLNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLpTWM2OD13LkC2PVA{KM7:TR?=	M3[2WnNCVkeHUh?=
AU565	NWnzd3VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVruRm9pUUN3ME21MlA6PzB{IN88US=>	NHT3RYVUSU6JRWK=
DMS-79	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPObHR3UUN3ME21MlE{QDh\|IN88US=>	MlLhV2FPT0WU
DK-MG	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;adGFbUUN3ME21MlE5PDN6IN88US=>	NF3ud29USU6JRWK=
HuCCT1	MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXUZ3BjUUN3ME21MlI{QDV4IN88US=>	MV7TRW5ITVJ?
HT-144	M4C0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PVTGlEPTB;NT6yOFk5PyEQvF2=	MXnTRW5ITVJ?
M059J	M1jYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknZTWM2OD13LkK1O\|Yh\|ryP	NWHC[mVoW0GQR1XS
COLO-792	NILhZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;TS2lEPTB;NT6yOlM2PiEQvF2=	NF7uZ2VUSU6JRWK=
SF539	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYq2e2N2UUN3ME21MlI3PjN{IN88US=>	MlvPV2FPT0WU
SK-UT-1	NIDBR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLodWd3UUN3ME21MlI4PzVzIN88US=>	MYjTRW5ITVJ?
NCI-H1703	NGi3cnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3:xcGlEPTB;NT6zOVgzPiEQvF2=	NIjtS4ZUSU6JRWK=
SW837	NHXPeppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTVwM{e4O\|gh\|ryP	M3LBUXNCVkeHUh?=
U251	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3ST3ZKSzVyPUWuN\|kxQTZizszN	MmnvV2FPT0WU
SW1710	NUDWO4h{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXlZoRKSzVyPUWuOFE2PTRizszN	MnzlV2FPT0WU
NCI-H1299	NVnrTno2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[4b2lEPTB;NT60OlM{PSEQvF2=	NWTIW2o4W0GQR1XS
RVH-421	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlezTWM2OD13LkS5PVA5KM7:TR?=	NGjVXYRUSU6JRWK=
UM-UC-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;kR2lEPTB;NT62NlY2OSEQvF2=	MnvMV2FPT0WU
MDA-MB-175-VII	NUPQSIQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHzTWM2OD13Lk[0NFQyKM7:TR?=	MojqV2FPT0WU
KYSE-270	M3\Xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPYTWM2OD13Lk[2NFMyKM7:TR?=	Mk\MV2FPT0WU
COLO-668	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XL[2lEPTB;NT63NVMzKM7:TR?=	NHXnZm9USU6JRWK=
LN-405	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPzSWk1UUN3ME21Mlc{ODh3IN88US=>	NFW4XG1USU6JRWK=
HT-1376	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn;HTWM2OD13Lke4NFUzKM7:TR?=	NIrBN2pUSU6JRWK=
769-P	NFjUUm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGDERlJKSzVyPUWuPFY4OThizszN	NGXEXY1USU6JRWK=
HuP-T3	MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkjQTWM2OD13Lki4Olc4KM7:TR?=	MVHTRW5ITVJ?
MDA-MB-415	NHe0O3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvIV\|hmUUN3ME21MlkzOTN7IN88US=>	M{D2SXNCVkeHUh?=
MKN7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmqxTWM2OD13Lkm4PEDPxE1?	M2nrdnNCVkeHUh?=
KS-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfDTWM2OD13Lkm4PFM3KM7:TR?=	MWPTRW5ITVJ?
647-V	NHO1dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTC[XBoUUN3ME21Mlk6OTR6IN88US=>	M{PxU3NCVkeHUh?=
COLO-679	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfj[HlHUUN3ME22MlAxOjV3IN88US=>	M2q0SHNCVkeHUh?=
AN3-CA	MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXvTWM2OD14LkCzOFQyKM7:TR?=	NXfYR\|YzW0GQR1XS
C32	NGj3OXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTZwMUOwN\|Qh\|ryP	MUPTRW5ITVJ?
KM12	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fYXmlEPTB;Nj6yOFA6QSEQvF2=	MYPTRW5ITVJ?
KINGS-1	NFPXeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHNem5zUUN3ME22MlI3OTV{IN88US=>	MkDsV2FPT0WU
KYSE-410	NEDqVGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTZwM{C2OFUh\|ryP	M3XT[3NCVkeHUh?=
HPAF-II	M4m4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonPTWM2OD14LkO1OFgh\|ryP	NVnpUmQ1W0GQR1XS
LAN-6	NHj3OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;ySGlEPTB;Nj60PVY{OSEQvF2=	NVLlbG5XW0GQR1XS
LU-99A	MkTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHxe4RKSzVyPU[uOVU6QDlizszN	NUjTV5NOW0GQR1XS
SJSA-1	NGfiWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYjlOpFJUUN3ME22MlU3OzR5IN88US=>	MnTPV2FPT0WU
MSTO-211H	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELZWY9KSzVyPU[uO\|IzOzNizszN	NILHfIFUSU6JRWK=
SW900	NUXaU\|A1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTZwN{[yNlEh\|ryP	M4rm[3NCVkeHUh?=
LNCaP-Clone-FGC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz4OWhKSzVyPU[uPFA1ODNizszN	NV;tUGNvW0GQR1XS
OMC-1	M3jMWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfnOIlKSzVyPU[uPFU1ODJizszN	MnPYV2FPT0WU
IST-MEL1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPnVmhCUUN3ME22Mlg6PjZ7IN88US=>	NHXiSphUSU6JRWK=
TE-9	M3nsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;iNYttUUN3ME22Mlg6QDR5IN88US=>	M{PjcXNCVkeHUh?=
NCI-H2030	NHL0Xm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;SXYt7UUN3ME22MlkyOjJ4IN88US=>	MX;TRW5ITVJ?
BFTC-909	M3TrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTa[Id2UUN3ME23MlAxPjRzIN88US=>	M17kWXNCVkeHUh?=
NCI-SNU-5	MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTdwMEKxOVkh\|ryP	NUP1XJNIW0GQR1XS
TE-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVj2UHdKUUN3ME23MlAzQDhzIN88US=>	M1jJS3NCVkeHUh?=
SK-MES-1	MnXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTdwMEW0Nlch\|ryP	M4rMcXNCVkeHUh?=
SHP-77	NFjuUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkH0TWM2OD15LkGzPVUzKM7:TR?=	NEezeJFUSU6JRWK=
NCI-H1623	NFnVWI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjVTWM2OD15LkG0NFczKM7:TR?=	MWTTRW5ITVJ?
TE-11	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LicWlEPTB;Nz6xOVE5PCEQvF2=	M{\0[XNCVkeHUh?=
EKVX	M2H0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHLTXhYUUN3ME23MlE6OjZ5IN88US=>	MlHsV2FPT0WU
OVCAR-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTdwMkGxN\|Mh\|ryP	MofnV2FPT0WU
C3A	M4f2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkmwTWM2OD15LkO0OVIh\|ryP	NWDYUm12W0GQR1XS
CFPAC-1	M2LYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3qxVmlEPTB;Nz6zOlIzOiEQvF2=	MlnMV2FPT0WU
MG-63	NGnzdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\TXZh{UUN3ME23MlQyQDR7IN88US=>	NFTPbllUSU6JRWK=
KYSE-140	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTdwNESwOlEh\|ryP	M3;FSHNCVkeHUh?=
MPP-89	NXvJToE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv5W41mUUN3ME23MlU6PzJ7IN88US=>	NIjIPWNUSU6JRWK=
COLO-824	NFnVVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\iTWM2OD15LkeyPFY{KM7:TR?=	NXGzXVdHW0GQR1XS
SiHa	MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfQSo9pUUN3ME23Mlg{PzB5IN88US=>	MmP2V2FPT0WU
SNU-387	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfhS4FKSzVyPUeuPFU{PDdizszN	MYrTRW5ITVJ?
A172	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnLT\|lKSzVyPUeuPFYyPzJizszN	NWD4Xnh{W0GQR1XS
COLO-680N	M4PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEfjb3FKSzVyPUeuPVE4OyEQvF2=	NHi4eFJUSU6JRWK=
HCC1395	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2D2cGlEPTB;OD6wOVQ2OiEQvF2=	NV[yfldrW0GQR1XS
NCI-H28	MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Moj4TWM2OD16LkC1PVY{KM7:TR?=	MXvTRW5ITVJ?
LC-2-ad	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\ETWM2OD16LkKxPVM4KM7:TR?=	NFnZV3BUSU6JRWK=
S-117	NYX2bZRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFflc5dKSzVyPUiuNlU{PTNizszN	NEDaNoxUSU6JRWK=
NCI-H1838	M{nON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRThwMkW3PFEh\|ryP	NHz4OFhUSU6JRWK=
PANC-10-05	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDMTWM2OD16LkO3NFQ4KM7:TR?=	Mo\nV2FPT0WU
KALS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRThwNUC5Nlgh\|ryP	MUHTRW5ITVJ?
LS-1034	NGfaZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrCelZvUUN3ME24MlU4PDN5IN88US=>	NYH0em5YW0GQR1XS
TGBC1TKB	M3L3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTFeYJ3UUN3ME24Mlc{PTN3IN88US=>	Ml;kV2FPT0WU
OE19	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYmyWFl[UUN3ME24Mlc3OjZ{IN88US=>	M3\vWXNCVkeHUh?=
D-502MG	M{f6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoThTWM2OD16Lke2PVk1KM7:TR?=	MVzTRW5ITVJ?
JEG-3	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPUTJJKSzVyPUiuO\|g3OThizszN	M1ToOXNCVkeHUh?=
DBTRG-05MG	NGPZ[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mli1TWM2OD16Lki3OVY2KM7:TR?=	NYfKOZVxW0GQR1XS
ME-180	NVHSUJVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvIRpNKSzVyPUmuNFY4OjVizszN	Ml60V2FPT0WU
NCI-H1573	NWLLe2hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HQemlEPTB;OT6xNFU{OiEQvF2=	MkDvV2FPT0WU
HCC2998	Ml7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXLzXJlMUUN3ME25MlE{PjhzIN88US=>	NInCc2lUSU6JRWK=
ACHN	NHTiPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mo\OTWM2OD17LkK0PVc2KM7:TR?=	M3TiSHNCVkeHUh?=
D-392MG	NH63OnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTlwMkW3NVUh\|ryP	M4nuV3NCVkeHUh?=
no-11	MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXVTWM2OD17LkK2NFI5KM7:TR?=	M37wTnNCVkeHUh?=
KLE	M3XZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jlNGlEPTB;OT6zNlI{OiEQvF2=	MXzTRW5ITVJ?
Calu-6	NIPsOmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jZdmlEPTB;OT6zO\|UzQCEQvF2=	M3XqOnNCVkeHUh?=
LB831-BLC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PVbGlEPTB;OT60OVE4OSEQvF2=	M1HsbnNCVkeHUh?=
SW684	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrYTWM2OD17LkS2NVE3KM7:TR?=	NH\0R\|FUSU6JRWK=
SH-4	NU\2[WlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3TbnNNUUN3ME25MlQ6OzZ2IN88US=>	MlHPV2FPT0WU
IST-MES1	MoHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\LO2lEPTB;OT61NVY1PCEQvF2=	M4ryeHNCVkeHUh?=
Saos-2	NYLtVGJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\QTWM2OD17LkWyNVk2KM7:TR?=	NWW3TZE6W0GQR1XS
NCI-H2087	NGrzZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTlwNkezOVIh\|ryP	MlzSV2FPT0WU
SCC-9	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3iTWM2OD17LkexPFE3KM7:TR?=	NYj2bJdxW0GQR1XS
MFE-280	NI[wWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDMVG9TUUN3ME25MlczPzh3IN88US=>	M{jQNHNCVkeHUh?=
BEN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zrcWlEPTB;OT64NlE2QSEQvF2=	MUfTRW5ITVJ?
CP50-MEL-B	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\wRmpqUUN3ME25MlkzPDN{IN88US=>	MmO5V2FPT0WU
SK-MEL-28	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDhTWM2OD1zMD6wNVk{KM7:TR?=	MofJV2FPT0WU
NCI-H2452	NEH4dFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTofnNOUUN3ME2xNE4yPiEQvF2=	MkLPV2FPT0WU
NCI-H1395	NVvBR2xjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\6UINCUUN3ME2xNE4yPzhizszN	NHTGW\|BUSU6JRWK=
NCI-H2052	NX\3WWFGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTFyLkG4PFIh\|ryP	M2XNTXNCVkeHUh?=
A375	NUDPSVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTFyLkK0OVIh\|ryP	M1HTV3NCVkeHUh?=
HCC38	NGfK[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrXRYZKSzVyPUGwMlMzOiEQvF2=	MlnUV2FPT0WU
LK-2	NY\3[2VqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;UOI1KSzVyPUGwMlQzODhizszN	MVLTRW5ITVJ?
SF126	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP1NmozUUN3ME2xNE41PzJ5IN88US=>	M4THdHNCVkeHUh?=
SK-MEL-1	M3zyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTFyLke4N\|gh\|ryP	NVLJ[nBuW0GQR1XS
ACN	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjIO5R1UUN3ME2xNE45Pjd7IN88US=>	NXvHfW9KW0GQR1XS
BB30-HNC	NXXSO45LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\mUnBKSzVyPUGwMlg4OTFizszN	MkLJV2FPT0WU
NCI-H747	NF\UVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LSNmlEPTB;MUCuPFc1PiEQvF2=	NWHodJlzW0GQR1XS
KYSE-150	NWLtNIN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LXSGlEPTB;MUGuNFM5PyEQvF2=	MVzTRW5ITVJ?
D-247MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTpTWM2OD1zMT6xNFA6KM7:TR?=	NVjnNXRwW0GQR1XS
BxPC-3	M{PJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIizRlZKSzVyPUGxMlM4PDdizszN	M33r[nNCVkeHUh?=
SK-MEL-30	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTiTXZKSzVyPUGxMlQxPzlizszN	M4PLdnNCVkeHUh?=
CAS-1	NV7lN2RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3hVZY5UUN3ME2xNU41OTB7IN88US=>	NG\5UGNUSU6JRWK=
no-10	NYXTSHM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;sdYVKSzVyPUGyMlEzOTdizszN	NXfN[JRRW0GQR1XS
NCI-H2405	NUPxeos6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLIT5JKSzVyPUGyMlIxOzZizszN	NUOwOGhqW0GQR1XS
KGN	M3XiOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfsXplKSzVyPUGyMlI6ODFizszN	NGXTdYJUSU6JRWK=
BB49-HNC	NX7kTGhVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PYNmlEPTB;MUKuN\|k2PiEQvF2=	MlHVV2FPT0WU
NCI-H1693	M1nv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTF{LkW4NVYh\|ryP	NG\rVYpUSU6JRWK=
RO82-W-1	NUfnbZVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fi[WlEPTB;MUOuNFY1QSEQvF2=	MV;TRW5ITVJ?
CAL-85-1	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlTaTWM2OD1zMz60N\|k6KM7:TR?=	NHnZXW1USU6JRWK=
H-EMC-SS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe1NFZ2UUN3ME2xN{46OTB2IN88US=>	NULxTIdYW0GQR1XS
SW1783	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHwfIZKSzVyPUG0MlI{QTFizszN	M{\IUnNCVkeHUh?=
LB771-HNC	M1PLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXpS2xKSzVyPUG0MlQyQSEQvF2=	NIKyXI1USU6JRWK=
HCC70	M1\Z[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHtTWM2OD1zND60NlM{KM7:TR?=	MlW2V2FPT0WU
KNS-81-FD	M{TifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTF2LkewOFUh\|ryP	MlzoV2FPT0WU
KYSE-520	M4fXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHtO3BKSzVyPUG0MlkzPyEQvF2=	NUTl[Y9IW0GQR1XS
TGBC24TKB	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Ta[GlEPTB;MUSuPVU{QSEQvF2=	MkDWV2FPT0WU
SNB75	NFjYPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPke3loUUN3ME2xOU4xPzJ7IN88US=>	M4nldXNCVkeHUh?=
SW872	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWLOfpFLUUN3ME2xOU4zOjF6IN88US=>	MXfTRW5ITVJ?
U031	Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PhPWlEPTB;MUWuPFAzQCEQvF2=	M2ewNHNCVkeHUh?=
ChaGo-K-1	NYC5TFU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrqe\|RKSzVyPUG1Mlg{PTlizszN	NYrPfHNrW0GQR1XS
NCI-H441	MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTF4LkCwN\|kh\|ryP	NVnvSZlQW0GQR1XS
TE-12	M3\HXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jTd2lEPTB;MU[uNVg4OyEQvF2=	MXzTRW5ITVJ?
NCI-H1755	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTF4LkW3N{DPxE1?	MnLuV2FPT0WU
KNS-42	Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDhWZZVUUN3ME2xOk43PTh7IN88US=>	M{facXNCVkeHUh?=
SK-PN-DW	MlWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jyUmlEPTB;MUeuOFIxOSEQvF2=	NEKyNpJUSU6JRWK=
NCI-H226	M1vpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjZ[oZKSzVyPUG3Mlk{PDVizszN	NFrQbnpUSU6JRWK=
K-562	M3PpZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrUPIpKSzVyPUG4MlY{OTdizszN	NGnHSWRUSU6JRWK=
A388	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTF7LkCzNFMh\|ryP	M1W3UnNCVkeHUh?=
ZR-75-30	MlKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nEcGlEPTB;MUmuNFk3QCEQvF2=	NF65UHFUSU6JRWK=
LU-135	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1i3fWlEPTB;MUmuNlY{PiEQvF2=	NV7T[odWW0GQR1XS
NCI-H2029	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYLqdZdbUUN3ME2xPU43ODJzIN88US=>	NWfC[2ZlW0GQR1XS
HT-1197	NVGzUFJDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTF7LkmyNlch\|ryP	Mki3V2FPT0WU
IGR-1	NFP6fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTJyLkOxNVch\|ryP	M2DwS3NCVkeHUh?=
U-87-MG	M3vKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPVXWF7UUN3ME2yNE43PDF\|IN88US=>	NITDZ5RUSU6JRWK=
NCI-H1304	M{[xfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4[1S2lEPTB;MkCuO\|UxOSEQvF2=	MWTTRW5ITVJ?
RCC10RGB	NHXq[2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJzLkK4Nlkh\|ryP	MmLDV2FPT0WU
NCI-H520	MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LZbWlEPTB;MkKuO\|YyOSEQvF2=	M3XCcXNCVkeHUh?=
SK-LU-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXTfoM5UUN3ME2yN{4xPzF6IN88US=>	NWL2W3lpW0GQR1XS
UACC-893	NInnNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXOTWM2OD1{Mz6xNFM5KM7:TR?=	M3u2OnNCVkeHUh?=
NCI-H2347	M4PNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWGxcHVnUUN3ME2yN{4zPjd2IN88US=>	NH\sS\|hUSU6JRWK=
U-118-MG	M1nuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFO0TpRKSzVyPUKzMlczOTdizszN	NIDtZ2RUSU6JRWK=
NCI-H596	NXy3fYFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2jmNWlEPTB;MkOuPVA2PSEQvF2=	NYmzcmlSW0GQR1XS
MZ1-PC	NVvWeHluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrxO5BKSzVyPUK0MlY4PTlizszN	NYLHfm1sW0GQR1XS
SW1417	M1nQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fKZ2lEPTB;MkWuNlQ6QCEQvF2=	NV\CW\|RmW0GQR1XS
NCI-H82	M4LJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrkdWhKSzVyPUK2MlQzQDhizszN	M1\iWnNCVkeHUh?=
COLO-678	NVr2VHR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1npOGlEPTB;MkeuOFkyQSEQvF2=	MoTWV2FPT0WU
KURAMOCHI	NUjoOnpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGPaUIlKSzVyPUK4MlEzPiEQvF2=	NYLITVh[W0GQR1XS
NCI-H1650	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIrGUlRKSzVyPUOwMlE6OjRizszN	NEnndnNUSU6JRWK=
HCC1954	M2WydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmCzTWM2OD1\|MT6zOlY3KM7:TR?=	NHHGdIJUSU6JRWK=
GAK	Ml;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLlXWRTUUN3ME2zNk4zPjF4IN88US=>	MV7TRW5ITVJ?
YAPC	MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPrTWM2OD1\|Mz63OlQ5KM7:TR?=	M4LtSnNCVkeHUh?=
NCI-H2228	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTN2LkO2NFUh\|ryP	MXnTRW5ITVJ?
VMRC-RCZ	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3WxVmlEPTB;M{[uN\|AzOiEQvF2=	MmDnV2FPT0WU
NMC-G1	M3PuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;LPI5XUUN3ME2zO{4xPTJ7IN88US=>	M3nvU3NCVkeHUh?=
D-336MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjtTWM2OD12MT64OFQzKM7:TR?=	NV7LT\|NzW0GQR1XS
UACC-62	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIe5N\|RKSzVyPUSyMlU2ODVizszN	M17XVHNCVkeHUh?=
C-33-A	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfoTWM2OD12NT6zNlU3KM7:TR?=	NHTvO\|ZUSU6JRWK=
HCC1937	M2rISWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3e1NmlEPTB;NEeuNVk2QCEQvF2=	NXrEeWxKW0GQR1XS
HDLM-2	NHu4SIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLnVYoxUUN3ME20O{4zOjh5IN88US=>	MWLTRW5ITVJ?
NCI-H727	NGTRWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzuTWM2OD12Nz6yOFUyKM7:TR?=	NFq5UZlUSU6JRWK=
NY	NFexd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTR7LkO5NFgh\|ryP	MX;TRW5ITVJ?
NCI-H2291	NW\DdmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zNUWlEPTB;NEmuPFMxOSEQvF2=	M3jrNXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Water	Insoluble
	Ethanol	'3 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	MK0683
Smiles	ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Withdrawn	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA)